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Background: There is no curative treatment available for the cause of dementia, and 
few drugs are approved for symptomatic treatment. In addition, knowledge about 
prognosis related to hospitalization and mortality is scarce in patients with dementia. 
This is especially true for patients with dementia with Lewy bodies and Parkinson’s 
disease dementia. They have many of the same clinical and pathological features and 
are often referred to as Lewy body dementia. Aim: To increase knowledge about 
pharmacological treatment and prognosis related to hospitalization and mortality in 
patients with mild Alzheimer’s disease and Lewy body dementia. Methods: Analysis 
of data from the DemVest study, a longitudinal cohort study in Western Norway. 
From March 2005 until April 2007 all consecutive referrals to secondary care 
outpatient clinics in geriatric medicine and old-age psychiatry with mild dementia 
were asked to participate. From April 2007 to 2013, only patients with Lewy body 
dementia were included. The consensus criteria for dementia with Alzheimer’s 
disease, dementia with Lewy bodies and Parkinson’s disease dementia were used to 
set the final clinical dementia diagnosis. The baseline assessment included the 
recording of present drug treatment, demographic and clinical data assessment of 
comorbidity and cognition, and a battery of other neuropsychological tests.  
Results: Patients with LBD were found to have a significantly shorter time until first 
hospitalization, more days in the hospital and a shorter survival time after diagnosis 
compared to AD. Apart from the use of antidementia drugs, 45% of the patients used 
at least one psychotropic drug; polypharmacy was also identified in 45% of the 
patients. Few potentially inappropriate medications (n=48) and severe drug-drug 
interactions (n=4) were identified. Conclusion and clinical implications: Having 
Lewy body dementia was associated with a higher risk of hospitalization and 
mortality. Polypharmacy and psychotropic drug use were common in mild dementia, 
but were not found to be associated with hospitalization or mortality. Early diagnosis 
of dementia may provide opportunities for more streamlined care and appropriate 
drug use which in turn can potentially improve the prognosis of patients with 
dementia. 
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1. Introduction  
In 2012, when this project was initiated, polypharmacy and the potentially negative 
effects of medication on older people were receiving a lot of attention. A year before, 
the Norwegian directory of health initiated the patient safety campaign “I trygge 
hender 24/7”. In this campaign, there were several actions to ensure safer drug 
treatment. Around the same time, the Norwegian directory of health published 
national guidance on how to perform a medicine review [4]. Additionally, screening 
tools to detect inappropriate medications had been published, both nationally and 
internationally [5, 6]. The importance of appropriate drug therapy was also a focus 
area in the Dementia Plan 2020 [7], which was published a few years after the project 
was initiated. The use of psychotropic drugs and problems related to discontinuation 
were highlighted as challenging areas [7]. However, there were little knowledge 
about medication use and prognoses related to hospitalization and mortality in home-
dwelling people recently diagnosed with dementia. The majority of the published 
studies included patients from nursing homes, who had more severe dementia. 
Increased knowledge about the course of the dementia may lead to better utilization 
of resources in the health care system and enable clinicians to better inform patients 
and caregivers. Further, receiving a dementia diagnosis may reduce stress in patients 
and caregivers as a dementia diagnosis leads to professional help which provides 
knowledge about the disease and treatment options. An early diagnosis may empower 
people to make decisions related to care and treatment, before the disease has 
progressed too far [8].  
This thesis focuses on aspects related to pharmacological treatment and prognosis in 
people with Alzheimer’s disease (AD) and Lewy body dementia (LBD), measured by 




Dementia is one of the greatest health care challenges of the 21st century [9]. In 2018, 
50 million people were estimated to be living with dementia - a number that is 
expected to triple by 2050 [10]. Currently, no published epidemiologic studies 
evaluate the number of people with dementia in Norway. The estimate is believed to 
be somewhere between 80.000 to 104.000 people [11]. However, a large ongoing 
prevalence survey is expected to be published in the summer of 2020. 
The International Statistical Classifications of Diseases and Related Health Problems 
(ICD-10), published by the World Health Organization, defines dementia as a 
syndrome due to disease of the brain, usually of a chronic or progressive nature [12]. 
For a dementia diagnosis, impairment must be present in at least two cognitive 
domains. Memory is most often impaired, and other frequently affected domains 
include visuospatial, language, and executive functions. In addition, the impairment 
must represent a decline from the prior level of function and affect everyday activity. 
Evaluation of possible dementia requires a medical history and a cognitive and 
neurologic examination [13]. 
There is no curative treatment for dementia, and the reason why some people, but not 
others, develop dementia is unknown, though increasing evidence suggests that many 
potentially modifiable lifestyle-related factors such as obesity, diabetes, and smoking, 
increase the risk of dementia. Reducing these risk factors might prevent or delay the 
development of dementia in some cases [8]. Dementia negatively impacts the persons 
affected and their families; as the disease progresses, more health and social care is 
needed, which will have consequences for the health care system [8]. 
Dementia is a heterogeneous condition and may be caused by different medical and 
neurological diseases [14]. AD is the most common cause of dementia, followed by 
vascular dementia and dementia with Lewy bodies (DLB). Mixed dementia is also 
common and is diagnosed when the boundaries between different forms of dementia 
are more unclear [8]. DLB together with Parkinson’s disease dementia (PDD) are 
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often referred to as LBD, as both forms of dementia are characterized by Lewy body 
pathology [15] and share many of the same clinical and pathological features [16]. 
The focus of this thesis is on AD and LBD. Other forms of dementia will not be 
further addressed. The terms DLB and PDD will be applied when discussing these 
diseases specifically, otherwise LBD will be applied, which includes patients with 
DLB and PDD. 
1.2 Alzheimer’s Disease 
1.2.1 Epidemiology 
AD is the most common form of dementia, accounting for 50-75% of all dementia 
cases [17]. In Europe, the prevalence of AD for those above 65 years is estimated to 
be 5.1%, with a higher prevalence reported for women than men (7.1% vs 3.3%) [18]. 
The prevalence increases with age; 1% of individuals between 65-74 years are 
estimated to have AD, with an increase of up to 22% for those above 85 years [18].  
1.2.2 Pathology 
The first description of AD was made in 1907 by Aloysius Alzheimer [19], who 
described the symptoms of a 51-year-old woman. After her death Alzheimer 
examined the brain and discovered the amyloid plaques and neurofibrillary tangles. 
These are now the two core pathological hallmarks of AD [20]. Amyloid- peptides 
are accumulated into extracellular plaques, while the formation of intraneuronal 
neurofibrillary tangles is due to hyperphosphorylation and aggregation of the tau 
protein [20]. These changes develop gradually and lead to synaptic loss and brain 
atrophy in the affected brain regions [21]. The hippocampus plays an important role 
in the consolidation of new memories and spatial orientation and is, together with 
adjacent regions, typically the first region of the brain to be affected by 
neurofibrillary tangles [21]. 
1.2.3 Clinical features  
AD is characteristic by insidious onset and gradual decline of cognition. Deficits in 
memory and executive function are the most typical presenting symptoms of AD [9]. 
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A more atypical presentation is a non-amnestic presentation where problems related 
to language, visual, practical or executive problems are more prominent than the 
memory impairment [9]. Atypical presentation, with relatively preserved memory at 
disease debut, is present in approximately 6–14% of all AD cases [22]. 
Non-cognitive symptoms such as neuropsychiatric symptoms are frequent in patients 
with AD [23], even at the mild stage [24]. Neuropsychiatric symptoms include for 
example delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, 
apathy, disinhibition, irritability/lability, aberrant motor activity, appetite disorder, 
sleep disorder [25]. In AD, apathy is the most common neuropsychiatric symptom, 
followed closely by depression, aggression and anxiety [23].  
1.2.4 Diagnostic criteria 
The National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
proposed the first diagnostic criteria for AD in 1984 [26] and revised them in 2011 
[27]. The 1984 criteria have been applied in several pathological studies, and the 
sensitivity and specificity have been found to be 81% and 70%, respectively, when 
one is distinguishing between AD and no dementia [28]. However, the criteria have 
been found to be less accurate when one is distinguishing between different types of 
dementia (23-88%) [20]. In 1984, pathological changes could not be measured in 
vivo. Therefore, a definite diagnosis of AD was possible only after death, and the 
1984 criteria focused only on clinical symptoms [26]. The 2011 criteria include 
clinical symptoms, but combine them with biomarkers of AD pathology (A42, total 
tau and phosphorylated tau), which are found in the cerebrospinal fluid [27]. These 
biomarkers have made it possible to diagnose AD pathology in vivo. In addition, the 
new criteria have enabled the diagnosis of AD prior to onset of dementia [27]. 
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1.3 Lewy body dementia 
1.3.1 Epidemiology 
Dementia with Lewy bodies 
There are no robust epidemiological studies of DLB, but the disease is considered the 
second most common neurodegenerative dementia disorder [29]. In the community, 
DLB has been estimated to account for 4.2% of all dementia cases, and to account for 
7.5% of all dementia cases known to secondary care [29]. However, the reported 
proportion of DLB among patients with dementia has a wide range (0-23%). Studies 
including more specific instruments and biomarkers to identify DLB, including 
dopamine transporter imaging and screening for rapid eye movement (REM) sleep 
behavior disorder, have reported more narrow estimates (10-24%) [15, 29].  
Parkinson’s disease with dementia 
Among all dementia cases, the proportion of PDD is estimated to be 3-4% [30]. In 
addition, mild cognitive impairment is common in Parkinson’s disease, and often 
progress to dementia [31]. The prevalence of PDD in patients with Parkinson’s 
disease is believed to be around 25%, and the risk of developing PDD increases with 
age [15].  
1.3.2 Pathology  
LBD is characterized by Lewy bodies which are spherical aggregates of protein that 
accumulate in the neurons of the brain. The protein alpha-synuclein is the major 
constituent of Lewy bodies [15]. Lewy bodies are found in the substantia nigra and 
the brainstem ganglia, as well as in the limbic structures and neocortex Additionally, 
pathological features of AD may be present in patients with PDD and DLB [15].  
1.3.3 Clinical features  
As in AD, the onset is insidious and there is a gradual development of symptoms [32, 
33]. LBD may be challenging to diagnose in the early stage due to difficulties in 
differentiating between DLB and AD, and to detect in a timely manner when patients 
with Parkinson’s disease develop cognitive impairment [15].  
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Dementia with Lewy bodies 
Early symptoms of DLB may be deficits related to attention, executive function, and 
visual processing. Memory impairment, which is one of the primary symptoms of 
AD, is not always present in the early stage of DLB [32]. Core clinical features of 
DLB are fluctuating cognition, visual hallucinations, Parkinsonism, and REM-sleep 
behavior disorder [16].  
Cognitive fluctuations can also be present in other forms of dementia, but are more 
frequent in patients with DLB [16] and have been reported to be present in almost 
50% of patients with DLB at the time of diagnosis [34, 35]. Fluctuations in DLB can 
manifest in many different ways and occur spontaneously [16]. The fluctuations can 
last anywhere from a few minutes to several days. In between these fluctuating 
episodes, the patient often function normally [36]. Hallucinations are more common 
in patients with DLB, as compared to patients with AD [24]. The hallucinations are 
often well formed and often feature children or animals [15]. REM-sleep behavior 
disorder occurs in around 20% of patients with DLB [37] and is characterized by 
dream-enactment due to loss of normal muscle atonia during REM-sleep. The dreams 
are often realistic and scary and the reenactment may cause harm to the patient or 
sleep partner [38].  
Supportive clinical features are severe neuroleptic sensitivity [16] which can occur in 
some patients with DLB treated with antipsychotics [39]. This features is 
characterized by sudden onset of sedation, increased confusion, rigidity, and 
immobility, potentially causing death within a few days or weeks [40]. 
Antipsychotics act on dopamine D2 receptors and the density of these receptors has 
been found to be significantly reduced with increasing Lewy body pathology and is 
suggested to explain the neuroleptic sensitivity [41]. Other supportive clinical 
features include severe autonomic dysfunction, e.g. orthostatic hypotension, postural 
instability, repeated falls, syncope, apathy, anxiety, systematized delusions, excessive 
daytime sleepiness and depression [16]. 
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Parkinson’s disease with dementia 
Parkinson’s disease is characterized by motor symptoms such as resting tremor, 
bradykinesia, rigidity and postural instability [42]. The presence of dementia in 
addition to well-established Parkinson’s disease are the two core features of PDD. 
Associated clinical features in PDD are deficits in cognitive features related to 
attention, visuospatial functions, executive functions, and memory. The core function 
of language is largely preserved, but problems with word finding and reduced 
understanding of complex sentences may be present [33]. Behavioral features include 
apathy, hallucinations, delusions, personality changes and excessive daytime 
sleepiness [33].  
Impairment of attention is an early and prominent symptom with fluctuations similar 
to DLB [43] and is associated with impairment in everyday activities [44]. 
Neuropsychiatric symptoms are frequent [45] and apathy, impairment of attention 
and visuospatial function is often more prominent in patients with PDD compared to 
AD patients. Visual hallucinations are often well-formed figures, similar to those 
experienced by patients with DLB [46].  
1.3.4 Diagnostic criteria  
Dementia with Lewy bodies  
DLB is the most recently defined form of non-AD dementia. DLB is not part of the 
ICD-10 [12] but is included in the ICD-11 criteria, which have been published, but 
not yet implemented [47]. In addition, DLB was not included in the Diagnostic and 
Statistical Manual for Mental Disorders (DSM) before the fifth version, which was 
published in 2013 [48].  
The first diagnostic criteria for DLB were published in 1996 [36], and have since 
been updated, in 2005 [39] and in 2017 [16]. The first diagnostic criteria were found 
to have acceptable specificity, but low sensitivity. Therefore, to increase sensitivity, 
REM-sleep behavior disorder was added as a supportive feature to the 2005 criteria 
and further included as a core clinical feature in the 2017 criteria. Further, 
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hypersomnia, typically presented as daytime sleepiness, and hyposmia, partial loss of 
sense of smell were added as supportive features to the 2017 criteria [16].  
Severe neuroleptic sensitivity was listed as a suggestive feature in the 2005 criteria 
and then changed to a supportive feature in the 2017 criteria. There was a black-box 
warning issued by the US Food and Drug Administration in 2008 about the use of all 
antipsychotics to elderly people [49]. This has reduced the prescribing of 
antipsychotics to patients with DLB; therefore, its diagnostic usefulness is limited 
[16]. A definite diagnosis of DLB is not possible as there are no direct measure of 
alpha-synuclein pathology [32]. In the 2017 criteria, the suggestive features were 
replaced with indicative and supportive biomarkers. Presence of indicative 
biomarkers have shown to increase diagnostic specificity in DLB, while supportive 
symptoms and biomarkers carry less diagnostic weight, but may be important when 
making clinical decisions [16].  
A clinical diagnosis of DLB is diagnosed as either probably or possible, depending on 
which clinical features are present. In the latest version, probable DLB is diagnosed if 
the patient has two or more core clinical features or has one core clinical feature and 
one or more indicative biomarkers. Possible DLB is diagnosed if one core clinical 
feature is present, but there are no indicative biomarkers. Possible DLB can also be 
diagnosed if at least one indicative biomarker is present, even though no core clinical 
features are present [16].  
Parkinson’s disease with dementia  
The International Parkinson and Movement Disorder Society has provided clinical 
diagnostic criteria for probable and possible PDD [33]. According to these criteria, 
the core feature of Parkinson’s disease and dementia must be present in both probable 
and possible PDD [33]. Probable PDD is diagnosed if the patient has at least two of 
the associated clinical features. Having at least one behavioral feature such as apathy 
or hallucinations, supports the diagnosis, although absence does not exclude probable 
PDD [33]. Possible PDD is diagnosed when the core symptoms are present and the 
attention is preserved, but the cognitive impairment is more atypical. For example 
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having aphasia or if retrieval of memory is not improved when a cue or word related 
to the information is given. Possible PDD is also diagnosed if the patient has features 
that make the diagnosis uncertain, e.g., comorbidity that may explain the cognitive 
impairment, or if the time interval from motor and cognitive symptoms is not known. 
Behavioral symptoms may be present, but not always [33]. 
In clinical practice and research studies, DLB and PDD are differentiated from each 
other in terms of in which order dementia and Parkinsonism occur. A PDD diagnosis 
should be given if the patient has well-established Parkinson’s disease, while a DLB 
diagnosis should be given if dementia occurs before, simultaneously with or less than 
one year since the Parkinson’s disease diagnosis [16, 33]. As the condition 
progresses, both conditions and underlying pathological changes become similar and 
can be more viewed as one condition rather than two different diseases [15]. 
1.4 Pharmacological treatment in dementia 
Currently, no medical cure or disease-modifying treatment are available to treat 
dementia. Clinical guidelines mainly recommend non-pharmacological treatment 
such as activities matched to interest or music therapy [8] as first line treatment, and 
pharmacological treatment should never be used instead of, but rather in combination 
with non-pharmacological interventions [50, 51]. Pharmacological treatment aims to 
curb the symptoms of disease progression by maintaining memory and functional 
abilities, reduce neuropsychiatric symptoms and postpone entry into institutional care 
settings [50]. 
1.4.1 Management of cognitive symptoms 
The degeneration of selected brain nuclei associated with dementia reduces the 
production of different neurotransmitters such as acetylcholine, which has been 
shown to have an impact on attention, memory and learning [52]. Today, four drugs 
are available, all of which are licensed to have symptomatic effect on cognitive 
symptoms in dementia. Three of the approved drugs, donepezil, rivastigmine, and 
galantamine, are cholinesterase inhibitors, which inhibit acetylcholinesterase and 
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prevent the degradation of acetylcholine. This increases the abundance of freely 
available acetylcholine in the synaptic cleft for cholinergic neurotransmission 
resulting in improved cognitive function and activity of daily living [52]. 
Cholinesterase inhibitors are approved as a pharmacological treatment for patients 
with mild to moderate forms of AD. Clinical guidelines recommend starting 
treatment when a diagnosis of mild AD is made [51]. Common side effects are 
nausea, diarrhea, vomiting, anorexia, and abdominal pain [53]. To reduce the risk of 
side effects it is recommended that the dosing regimen be started with slow titration 
over the course of four to eight weeks. If side effects are experienced, the dosage may 
be lowered, or one could shift to another cholinesterase inhibitor. Although there are 
some pharmacodynamic differences between the different cholinesterase inhibitors, 
the efficacy of these drugs appears similar [54]. 
Rivastigmine is also licensed for patients with PDD, but not for those with DLB. 
However, degeneration of cholinergic neurons also appears in DLB [55] and 
cholinesterase inhibitors are recommended as a first-line treatment in patients with 
PDD and DLB [51, 56]. Meta-analyses report that cholinesterase inhibitors benefit 
patients with PDD and DLB by improving cognitive function and the activity of daily 
living [57, 58]. However, high frequencies of side effects, such as nausea, vomiting, 
anorexia, and tremor, were reported, with a higher frequency in rivastigmine [57]. 
Glutamate is an excitatory neurotransmitter in the brain that can cause neuronal 
damage and death by over activating N-methyl D aspartate (NMDA) receptors. 
Memantine is an uncompetitive antagonist on the NMDA receptor [59] and is the 
fourth drug approved for treatment in patients with moderate to severe AD. 
Memantine has been found to be benefit patients with moderate to severe AD by 
improving cognition and reducing neuropsychiatric symptoms. Memantine is well 
tolerated and has few side effects in patients with AD. The main side effect reported 
is dizziness [60]. Further, combining a cholinesterase inhibitor with memantine is 
recommended in several countries, particularly as dementia progresses [61]. In 
patients with LBD, the use of memantine is reported to be safe, though evidence 
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concerning its benefit is less conclusive [57, 58]. Therefore, there are still 
uncertainties to whether treatment with memantine could benefit patients with LBD 
[62]. 
1.4.2 Management of neuropsychiatric symptoms 
The majority of patients with dementia will, at some point during the disease, 
experience neuropsychiatric symptoms [63], and are common even in the mild stage 
of dementia [24]. Neuropsychiatric symptoms are assumed to have multifactorial 
causes. Pain, dehydration and infections are some of the most common causes of 
neuropsychiatric symptoms [63]. These symptoms are often distressing for the 
patient, and challenging for the caregiver and may cause the patient to be transferred 
to institutional care. If neuropsychiatric symptoms are present, a thorough assessment 
and management of underlying causes and non-pharmacological measures should be 
performed before initiating any pharmacological treatment [63]. 
Risperidone is approved for the treatment of aggression in patients with AD in most 
European countries [64], but there is no other licensed pharmacological treatment for 
neuropsychiatric symptoms. Nevertheless, psychotropic drugs are frequently 
prescribed off-label to improve or relieve neuropsychiatric symptoms in dementia 
[65]. Pharmacological treatment may be necessary if patients still have severe 
neuropsychiatric symptoms, even after trying non-pharmacological interventions 
[62]. 
Donepezil or rivastigmine is recommended to treat severe neuropsychiatric symptoms 
in patients with LBD [62]. If psychotic symptoms are still present after treatment with 
cholinesterase inhibitors, the use of antipsychotics may be considered [62]. 
Antipsychotics have been used to treat hallucinations, but high incidences of severe 
reactions, such as stroke, pneumonia and reduced survival, were experienced [66]. 
This especially applies to patients with LBD [67], and there is no evidence to support 
the use of antipsychotics in these patients [62]. In relation to this, neuroleptic 
sensitivity was listed as a suggestive feature in the 2005 DLB criteria [39] as 
described in section 1.3.3 and 1.3.4. In AD, treatment with antipsychotics has been 
reported to have moderate benefits, but also to cause serious adverse events including 
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Parkinsonism, sedation, pneumonia, and an increased risk of stroke and death [68, 
69].  
Before initiating treatment with antipsychotics, it is recommended to cooperate with 
the patient, their relatives and caregivers to determine if potential benefits outweigh 
the risk of using antipsychotics [8]. A low dose of quetiapine is considered to be the 
safest choice for patients with LBD, although evidence concerning the effect is 
limited [62], while national guidelines recommend a very low dose of clozapine [51]. 
Clozapine is used to treat psychosis in patients with Parkinson’s disease and may 
potentially be beneficial in LBD. However, no trials have been performed [62]. In 
patients with AD, risperidone is recommended as first-line pharmacological treatment 
for severe psychotic symptoms such as hallucinations and delusions [70]. This is in 
line with the Norwegian national guideline [51]. 
Depression is common in patients with AD and LBD and has a negative impact on 
cognition and caregiver stress [8]. Few randomized controlled studies have included 
patients with dementia and there is not enough evidence to support the use of 
antidepressants in patients with dementia. Therefore, it is suggested that use be 
limited to patients with severe and disabling symptoms of depression [71]. If 
pharmacological treatment is necessary, a selective serotonin-reuptake inhibitor 
(SSRI) is the preferred choice of drug in both forms of dementia. Further, tricyclic 
antidepressants should be avoided due to anticholinergic side effects [50, 56]. 
1.5 Prognosis of dementia 
With the expected increase in the number of people with dementia [72], more 
knowledge about prognosis among various forms of dementia was needed. Increased 
knowledge about prognosis may empower patients with dementia and their families 
to make arrangements and timely decisions about treatment, accommodation, and 
care. Additionally, it may lead to more optimal advice from clinicians [73]. 
Prognosis is a broad term and consists of several aspects, e.g., quality of life, the 
activity of daily living, and nursing home placement. Previous studies have 
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investigated the formal care [74], rate of deterioration of cognition [75], time until 
nursing home admission [76] and caregiver distress [77], and have shown that DLB 
patients have poorer prognosis compared to patients with AD. These findings have 
been confirmed by some studies [78-80], but not by others [81]. However, there are 
also wide variations within the disease groups, and hence, providing information 
about prognosis to individual patients may be difficult because of a large variation 
between patients and the diversity of factors affecting prognosis [82]. 
This thesis focuses on prognosis related to hospitalization and mortality after a 
dementia diagnosis. These outcomes will be further addressed in this section.  
1.5.1 Hospitalization in dementia  
The hospitalization rate in a population is known to increase with age [83]. Patients 
with dementia are reported to have a higher hospitalization rate compared to people 
without dementia, regardless of age [84]. Further, evidence from English health 
records showed that around 50% of all patients with dementia were admitted to a 
hospital the first year after diagnosis [84].  
An episode of hospitalization may be stressful for patients with dementia [85], and 
they may receive inadequate treatment due to their impaired ability to communicate 
[13]. Further, an underlying medical condition can exacerbate confusion. This can be 
challenging to detect in LBD due to fluctuating symptoms related to the disease [82]. 
In addition, combinations of multimorbidity [86] and severe neuropsychiatric 
symptoms [87] may challenge the medical treatment and care of patients with 
dementia. Hospitalization may also increase the risk of discharge to a higher level of 
care than was required before the hospitalization [88, 89]. Hence, preventing 
hospitalization should be one of the management goals for patients with dementia. 
In 2019, one of the first systematic reviews assessing the hospitalization rate and 
predictors of hospitalization was published [84]. The review included 34 studies 
including 277,432 patients with dementia. The majority of the studies included 
patients with AD or focused on all-cause dementia. Only one study with 194 patients 
with DLB was included in the review [90]. 
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In relation to the complex clinical features of LBD described in section 1.3.3, one 
might anticipate that patients with LBD will have a higher admission rate and a 
longer length of stay. However, comparisons of hospitalizations between patients 
with AD and LBD are scarce. The majority of them had small sample sizes, short 
follow-up times and have methodological differences [78, 81, 91]. The largest 
hospital study included 194 DLB patients. The study that patients with DLB had 
significantly higher admission rates compared to AD patients and the catchment 
population. In addition, patients with DLB had almost four more hospital days per 
person-year compared to AD patients [90]. 
Pharmacological treatment may affect the risk of hospitalization. A Swedish study 
reported that patients with dementia, using PIM, had an almost 90% (OR 1.88, 95% 
CI 1.03-3.34) increased risk of being admitted to hospital within one year compared 
to those who did not use PIM. [92], while another study found that patients with 
dementia using four or more medications had increased risk of hospitalization [93]. 
The use of a cholinesterase inhibitor (HR 0.87, 95% CI 0.67-1.14) and antipsychotics 
(HR 1.32, 95% CI 0.77-2.27) have been found to reduce and increase the risk of 
admission, respectively. Although, none of these predictors were statistically 
significant [94].  
More knowledge about hospital admissions in patients with different forms of 
dementia and what factors affect hospital admissions can hopefully benefit 
caregivers, patients and their relatives. 
1.5.2 Survival and mortality in dementia 
There is no medical cure and dementia is a chronic illness, leading to death as 
described in section 1.4.Therefore, a diagnosis of dementia imposes a great burden on 
the patient and their relatives and produces concern regarding the duration of time 
one has before death [73]. Patients with dementia have increased mortality [95]; 
survival time is decreased compared to the life expectancy of an average population 
of similar age and gender [96]. Knowledge of survival and predictors of mortality in 
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various forms of dementia may enable the health care system to better inform patients 
and relatives, to utilize resources, and plan for future care. 
In 2012, a systematic review reported that the survival time in patients with different 
causes of dementia ranged between one year and almost nine years [96]. This 
systematic review reported data from more than 11,000 patients, among who 65% 
(n=6370) had AD, close to 2% (n=186) had DLB and none had PDD [96]. Another 
review, published a year later [97], reported the median survival time from diagnosis 
in patients with all-cause dementia or AD as ranging from 3.3 to 6.6 years, which is a 
smaller range than that reported by Brodaty et al. [96]. Both reviews reported high 
heterogeneity between the included papers due to a variation in follow-up time and 
differences related to inclusion criteria and choice of index date. Therefore, they were 
not able to perform a meta-analysis. Todd et al. did not specify whether and how 
many of the patients were diagnosed with LBD [97]. Hence, knowledge about 
survival in different forms of dementia was still scarce when this project was 
initiated. Age and the male gender were considered predictors of mortality in 
dementia, but knowledge about specific predictors of mortality in different forms of 
dementia was limited [97]. 
1.6 Appropriate drug treatment in dementia 
Medications are a central part of care, and optimizing drug prescription has become 
an important public-health issue worldwide [98]. In Norway, appropriate medication 
use was a focus in the white Paper on Medicinal Products — Correct Use – Better 
Health, published in 2015 [99], and in the Dementia Plan 2020 [7]. To ensure 
appropriate medication in patients with dementia they call for a clearer division of 
roles and responsibility, adequate professional expertise, and better procedures. 
Several terms can be used to describe drug treatment such as inappropriate, good or 
poor [98]. In this thesis, the term “appropriate drug therapy” has been chosen. To 
assess the level of appropriateness several aspects should be evaluated. According to 
Spinewine et al., one should assess the drug treatment based on what the patient 
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wants, scientific and technical rationalism and the general good (family and societal 
consequences) [98]. Another approach is to focus on drug-related problems (DRP). 
The Pharmaceutical Care Network Europe Association (PCNE) defines a DRP as an 
event or circumstance involving drug therapy that actually or potentially interferes 
with desired health outcomes [100]. PCNE has developed a classification scheme for 
DRP to be used in research. The classification scheme divides DRP into three 
primary problems (see figure 1). 
 
Figure 1: Schematic layout of the PCNE Classification for Drug-Related 
Problems V9.00. The basic classification [100]. 
 
1.6.1 Polypharmacy  
Many chronic illnesses, such as dementia, are age-related and the risk of 
multimorbidity increases with age [86]. Medical treatment of chronic conditions is 
often managed using guidelines for single conditions. These guidelines aim to 
improve the clinical outcome, life expectancy, and quality of life. However, they may 
cause conflicting recommendations for people with more than one medical condition, 
and may lead to polypharmacy, the simultaneous use of several different drugs [86]. 
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Several definitions of polypharmacy are found in the literature, but the concomitant 
use of five or more different drugs is often defined as polypharmacy [101]. 
Polypharmacy is frequent among people over 65 years [102], and among community-
dwelling people, polypharmacy is found to be more frequent in people with dementia 
than without [103]. Polypharmacy may sometimes be appropriate, but each 
medication may complicate the medication regime and increase the risk of drug-drug 
interactions (DDI), hospitalization, and mortality [93, 104] leading to inappropriate 
polypharmacy. 
1.6.2 Potentially inappropriate medications and drug interactions 
During the last decade an increasing number of papers have focused on potentially 
inappropriate medications (PIM) (figure 2). 
 
Figure 2: Number of published papers in PubMed with the term "potentially 
inappropriate medications" in the title. 
PIM are drugs whose risks outweigh the benefits of their use or for which safer 
alternative exist [86] and they may lead to DRP [105]. Polypharmacy is one of the 
leading risk factors for using PIM [86]. Examples of PIM are benzodiazepines with 
long-half-lives and antipsychotics, which may be prescribed to treat various 
neuropsychiatric symptoms, such as hallucinations, aggression and sleep 
disturbances. Is using benzodiazepines, patients with dementia may experience 
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increased sedation, impaired cognition, or increased risk of falling [106]. Moreover, 
the use of antipsychotics is associated with an increased risk of mortality in patients 
with dementia [107]. In particular, patients with LBD are sensitive to these drugs, as 
described in sections 1.3.4 and 1.4.2. 
Several screening tools have been developed to identify PIM in elderly people, and a 
recent review identified 36 different screening tools [108]. Screening tools can either 
be based on specific criteria (explicit) or be judgment-based (implicit). Explicit 
screening tools can be used without any or little clinical judgment and can be applied 
without seeing the patient [98]. The Beers Criteria from the US [109] and the 
STOPP/START criteria from Ireland [110] are among the most cited explicit 
screening tools. Some of the drugs listed as PIM in these screening tools are 
unavailable in other countries. Therefore, national screening tools may be more 
applicable [111]. In Norway, the explicit screening tool Norwegian General Practice 
(NorGeP) criteria was published in 2009 [6]. 
Some of the screening tools also contain explicit criteria regarding DDI and drug-
disease interactions [108]. A DDI occurs when a drug affects another drug. The 
interaction leads to changes in the drug's pharmacodynamics or pharmacokinetic 
properties and may result in an altered therapeutic response. Both PIM and DDI have 
been associated with increased risk of hospitalization [92, 112]. Identifying PIM and 
DDI in patients with mild dementia may, therefore, be of vital importance. However 
the prevalence of PIM and DDI in patients with mild dementia living in the 
community was not well-described when this project was initiated. 
1.6.3 Medication adherence  
Medication adherence is an important therapeutic factor and is essential to 
determining medication effectiveness and safety [113]. Medication adherence is 
defined by the World Health Organization (WHO) as the extent to which a person’s 
behavior, corresponds with agreed recommendations from a health care provider 
[114]. 
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The definition embraces both over- and under-consumption of medications, the 
omission of a single-dose or deviation from prescribed time or dose intervals [115]. 
Multiple prescriptions of medications leading to polypharmacy increase the risk of 
non-adherence in older people [116]. Other factors that might negatively affect the 
medication adherence are complex drug regimens that include taking medications at 
different hours and with specific instructions [116] or problems with opening 
medicine containers [117]. Patients with dementia have an increased risk of non-
adherence [118] probably due to memory loss or impaired executive functions [119]. 
Low medication adherence may increase the risk of adverse events such as 
hospitalization and readmission [113]. Therefore, interventions that reduce 
complexity, such as changing drug formulations from several times a day to extended 
release formulations or fixed-dose combinations, may have a positive impact on 
adherence [116]. 
1.7 Literature search 
The comprehensive literature searches for this thesis ended on January 2020. Further, 
additional references were added when the text in was reviewed in June 2020. 
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2. Aim and objectives 
2.1 General aim 
The general aim of this thesis was to increase knowledge about pharmacological 
treatment and prognosis related to hospitalization and mortality in patients recently 
diagnosed with AD and LBD. 
2.2 Objectives 
1) To examine the prevalence of polypharmacy, psychotropic drugs, PIM, and 
DDI and to identify potential variables associated with having PIM and DDI in 
patients recently diagnosed with mild dementia. 
2) To examine whether there are differences in hospitalization between patients 
with AD and LBD and to explore how demographic and disease related 
variables may explain these differences, as well as to compare hospitalization 
rates to those of an age-matched general population. 
3) To examine survival and identify predictors of mortality in patients with AD 
and LBD and to compare mortality rates with an age- and sex-matched general 
population. 
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3. Material and methods 
This thesis is based on data from the Dementia Study in Western Norway (DemVest), 
a longitudinal cohort study of people with mild dementia [120]. It consists of three 
papers. An overview of these papers is seen in table 1. 
Table 1: Overview of the papers included in this thesis 
AD Alzheimer’s disease, DLB Dementia with Lewy bodies, PDD Parkinson’s disease with 
dementia, Others Other forms of dementia 
3.1 Subjects and samples 
All referrals to outpatient clinics in old-age psychiatry and geriatric medicine were 
screened for patients with a first-time diagnosis of mild dementia. In addition, 
neurology clinics were asked to refer patients to the outpatient clinics. The inclusion 
criterion was a first-time diagnosis of mild dementia. Therefore, the patients had to 
have a minimum score of 20 on the Mini Mental State Examination (MMSE) [121] 






























































































and/or have a global score of 1 on the Clinical Dementia Rating scale (CDR-GS) 
[122]. As patients were in the early stage of their disease, the majority of them were 
living at home. Patients with normal cognition, mild cognitive impairment or 
moderate and severe dementia defined as MMSE <20 or CDR-GS=2 were excluded. 
Additional exclusion criteria were acute delirium or terminal illness, a recent 
diagnosis of a major somatic illness, or a previous diagnosis of with psychotic or 
bipolar disorders. 
The inclusion process was performed in two periods. The main inclusion period was 
from March 2005 to April 2007. In this period, 670 subjects were screened, of whom 
209 (31%) patients fulfilled the inclusion criteria and 461 (69%) cases were excluded. 
The reasons for exclusion were moderate or severe dementia (n=166), unwillingness 
to participate (n=102), mild cognitive impairment (MCI, n=79), normal cognition 
(n=48), depression and pseudo-dementia (n=24), newly diagnosed somatic or 
terminal disorder (n=14), bipolar disorder or psychosis (n=11), another neurological 
disorder (n=7), and delirium (n=4); in six cases there were missing data. The second 
inclusion period lasted from April 2007 to 2013. In this period only patients with 
DLB and PDD (n=57) were included in the study. In total, 266 patients completed the 
baseline assessment. Further, details on the recruitment process and diagnostic 
procedures are provided in Aarsland et al. [120]. The inclusion process in relation to 





Figure 3: Flowchart of the inclusion process in relation to the papers in this 
thesis. 
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3.2 Dementia diagnosis 
Dementia was diagnosed according to the Diagnostic and Statistical Manual for 
Mental Disorders, 4th edition (DSM-IV). The clinical diagnosis of AD, DLB, or PDD 
was made according to their respective guidelines and consensus criteria [26, 33, 39]. 
DLB and PDD share many clinical and pathological features [15] and were combined 
and referred to collectively as LBD in paper II and paper III. In paper I, PDD were 
grouped with other forms of dementia. In cases of disagreement, the final diagnosis 
was made as a consensus between specialists in geriatric medicine and geriatric 
psychiatry. The dementia diagnoses were re-evaluated during the clinical follow-up, 
which resulted in minor changes between the papers. 
3.3 Ethical considerations 
The DemVest study was approved by the Regional Committee for Medical and 
Health Research Ethics in Western Norway (REK ID 2010/633). Detailed 
information about the study was provided to the patient and caregiver. After the 
information was provided, written consent was obtained from the participants before 
their inclusion in the study. 
3.4 Overview of the samples in the three papers 
The study samples vary between the papers, and may also vary from other papers 
based on DemVest data. A reason for this is that DemVest is a longitudinal and 
ongoing study. Therefore, the database is continuously updated with new 
information, resulting in new versions of the database. Another reason is that some 
papers are based on final consensus diagnoses from 2017. In this version, 56 patients 
have pathological diagnoses. The pathological diagnoses showed consistency with the 
clinical diagnosis in over 80% of the cases, for patients with AD and LBD [123]. 
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3.4.1 Sample of paper I 
Paper I included patients from both inclusion periods. Of the 266 patients included, 
15 patients were excluded for different reasons (missing information about diagnosis 
(n=8), mild cognitive impairment (n=4), or moderate dementia (n=3)). Therefore, the 
study sample consisted of 251 patients, of whom 137 (55%) had AD, 78 (31%) had 
DLB and 36 (14%) had other forms of dementia. 
3.4.2 Sample of paper II 
In paper II, all patients with a diagnosis of AD, DLB or PDD were included. Of 266 
patients in DemVest, 24 patients did not want to participate, three patients lacked 
information about baseline MMSE or dementia diagnosis, six patients had mild 
cognitive impairment and two patients had too-severe dementia at baseline 
(MMSE<20). In addition, patients with other forms of dementia were excluded 
(n=30). This resulted in 201 patients included. 
3.4.3 Sample of paper III 
In the third paper, only patients from the first inclusion period were included, as this 
cohort was believed to better reflect the general population as compared to the entire 
cohort. The study sample consisted of 209 patients of whom 137 (66%) had AD and 
53 (25%) had LBD (DLB=42 and PDD=11), while 19 (9%) patients had other forms 
of dementia.  
3.5 Clinical assessments 
A thorough clinical assessment was conducted at baseline and afterward, annually 
until death or drop-out. A detailed and comprehensive battery of assessment 
instruments was applied and the use of standardized and validated instruments was 
emphasized. The main instruments used in the different papers will be described 
below. 
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3.5.1 Cognitive function 
The MMSE [121] assesses cognitive functions and was used as a screening test. It 
focuses on memory, attention, orientation, concentration and constructing ability. The 
first part requires only vocal response, while the second part contains verbal and 
written commands and figure copying. The questionnaire is administered directly to 
the patient. 
To stage the severity of dementia, the CDR [122] was applied. The CDR rates the 
impairment in six cognitive categories, in which memory is weighted the highest. The 
severity of dementia is presented as a CDR-GS rating of either no dementia (zero), 
questionable dementia (0.5), mild dementia (1), moderate dementia (2), or severe 
dementia (3). The total global score was calculated by an online algorithm [124]. 
3.5.2 Neuropsychiatric symptoms 
Neuropsychiatric symptoms were evaluated using the Neuropsychiatric Inventory 
(NPI) [125]. The inventory assesses twelve neuropsychiatric symptoms frequently 
occurring in patients with dementia. The assessment scale focuses on symptoms that 
have been present for the past month. If the symptom is present, the frequency (0-4) 
and intensity (0-3) of the behavior are determined. Frequency and intensity are 
multiplied to provide an item score for each symptom (0-12). Thereafter, a sum score 
is calculated by summing the item scores (0-144). The questionnaire was proxy rated 
by a next of kin and symptoms were considered to be present if the frequency x 
intensity score was greater than zero. 
3.5.3 Depression 
In paper III, the Montgomery and Aasberg depression rating scale (MADRS) was 
applied to assess depression [126]. The scale consists of ten questions, rated from 
zero to six. The score from each question is summed up to provide a total score (0-
60). The total score is found to be a valid measure of the severity of depression, even 
in patients with mild dementia [127]. 
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3.5.4 Physical comorbidity 
The cumulative illness rating scale (CIRS) [128] was applied to estimate the patient’s 
total illness burden at baseline. CIRS assesses the degree of impairment in 13 
different areas grouped after body systems and provides knowledge about the medical 
burden and its severity. The assessment was performed retrospectively on baseline 
data and medical records close to the baseline date. Most of the CIRS assessments 
were performed by a specialist in geriatric medicine. Later, another geriatrician 
assessed the remaining missing CIRS score (n=16). 
3.5.5 Psychotropic drugs and polypharmacy 
Medications were registered and classified according to the Anatomical Therapeutic 
Chemical classification system (ATC) [129]. Opioids (N02A), antipsychotics 
(N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), antidepressants 
(N06A), and antidementia drugs (N06D) were classified as psychotropic drugs. Most 
anxiolytics (N05B) and hypnotics (N05C) are benzodiazepines. Non-benzodiazepine 
sleeping pills (N05CF) also act via benzodiazepine receptors and were therefore 
classified together with N05BA and N05CD as benzodiazepines. Polypharmacy and 
psychotropic polypharmacy were defined as the concomitant use of five or more 
drugs [101] and the use of three or more centrally active drugs [6], respectively. The 
analysis was performed without knowledge of whether the medication was scheduled 
or taken pro re nata. Data on adherence to a prescribed medication and use of over-
the-counter drugs and dietary supplements was also lacking. 
3.5.6 Classification of potentially inappropriate medications and 
drug-drug interactions 
The NorGeP criteria were applied to assess the use of PIM. The NorGeP criteria 
consist of a list of pharmacologically inappropriate prescriptions for people over the 
age of 70 years; the list consists of 36 criteria, with 21 being single drugs and 15 
being drug-drug combinations [6]. 
DDI were identified using a prescription and expedition support database (FEST) 
maintained by the Norwegian Medicines Agency [130]. The applied interaction 
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database uses a three-point scale to classify DDI: 1) “Drug interaction only of 
academic interest”, 2) “Clinicians need to take precautions”, and 3) “Drugs should 
not be combined”. 
3.6 Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics versions 20, 23 and 
24. In paper III some analyses were performed in R version 3.4. 
3.6.1 Descriptive statistics 
Baseline and demographic variables were presented as counts and percentages of 
categorical variables, means and standard deviations (SD) for normal distributed 
continuous variables and medians and interquartile ranges (IQR) for non-normal 
continuous variables. 
3.6.2 Simple comparison 
Comparison between groups was performed using Pearson Chi-square tests or 
Fisher’s exact test if over 20% of the cells had expected count less than 5, 
independent samples t-test, or Mann-Whitney U tests as appropriate. The distribution 
of the data was checked using Kolmogorov-Smirnov statistics and simple scatter 
plots to determine whether parametric or non-parametric methods were most 
applicable. P <0.05 was considered statistically significant. 
3.6.3 Standardization 
In papers II and III, the observed number of admissions and deaths were standardized 
and compared to a reference population. Paper II standardized in relation to age, 
while paper III standardized in relation to both age and gender. In paper II, a 
standardized admission ratio (SAR) for the first year after inclusion was estimated 






SAR was estimated for both planned and unplanned admissions in the age groups 60-
74 years and 75 years or older. 





In paper II, data about all admissions in the same catchment area in the age group 60 
years or older, combined with population statistics from Statistics Norway [131], 
were used to determine the expected number of admissions in the study population. In 
paper III, the Norwegian population was applied as the reference population. The 
death rate for this population was given by Statistics Norway as deaths per 100,000 
population, stratified by gender and age for each year between 2005 and 2011 [132]. 
Rates for 2012 were not available at the time of analysis. Therefore, the 2011 death 
rates were extrapolated to 2012. Age groups were adjusted each year as the study 
participants aged throughout the course of the study. 
The interpretation of SAR and SMR is the same. A ratio of 1 indicates no difference 
between patients with dementia and the reference population, while a value higher 
than one (>1) or less than one (<1) than one indicates that patients in the study 
population have more or fewer admissions or deaths than the reference population. 
3.6.4 Regression models and survival analysis 
Logistic regression was applied to assess whether baseline characteristics were 
associated with having PIM or DDI. Having PIM and having DDI were defined as 
dependent variables and were dichotomous into either present or absent. First, a 
univariate model was constructed. Potential confounders were baseline 
characteristics. Second, a multivariable model was constructed including all potential 
explanatory variables from the univariate analyses with p <0.25. 
Differences in rate and length of hospitalizations between AD and LBD were 
assessed using negative binomial models, yielding incidence rate ratios (IRR). 
Similarly, differences in time to first hospitalization were analyzed with the Fine-
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Gray competing risk regression model yielding sub-distributional hazard ratios 
(SDHR). All models were adjusted for factors that could have an impact on 
hospitalization, such as age, gender, the severity of neuropsychiatric symptoms and 
depression. The factors were added stepwise. Social factors and comorbidities were 
included first, followed by dementia-related variables such as the severity of 
neuropsychiatric symptoms and depression. Lastly, medication variables were 
adjusted for. To better reflect the cumulative incidences of hospitalizations seen in 
the community, time under observation was not accounted for in paper II. Additional 
analyses in which death was treated as a censoring event were published as 
supplementary results. Treating death as a censoring event yields cause-specific 
hazard ratios (CSHR) instead of SDHR. 
Differences in survival from time of diagnosis were assessed using Kaplan–Meier 
curves with log rank tests. Cox regression models were applied to explore predictors 
associated with survival time. Baseline characteristics were included as predictors. 
As in the logistic regression analysis, univariable models were estimated before a 
multivariable model including all significant variables from the univariable models. 
The final Cox regression model was found to be acceptable with regard to 
multicollinearity and the assumptions of proportional hazards. 
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4. Results 
4.1 Paper I 
Nearly all patients (96%) used one or more medications at the time of dementia 
diagnosis and the median number of medications were four (IQR 2, 6). One or more 
psychotropic drugs were used by almost 70% of the patients. Excluding antidementia 
drugs, 45% of the patients were using one or more psychotropic drugs. See table 2 for 
an overview of the psychotropic drugs used at baseline. 
Table 2: Psychotropic drug use at baseline.  
Modified from paper I with DLB and PDD grouped together as LBD. 
 Drug group Whole sample AD LBD 
Other 
dementia P-value 
  N % N % N % N %  
ATC Psychotropic drugs* 113 45.0 56 40.9 47 49.5 10 52.6 0.34 
N06D Antidementia 105 41.8 69 50.4 34 35.8 2 10.5 0.001 
N06A Antidepressives  81 32.3 44 32.1 28 29.5 8 42.1 0.56 
N05A Antipsychotics 19 7.6 4 2.9 13 13.7 2 10.5 0.009 




Benzodiazepines  40 15.9 19 13.9 16 16.8 5 26.3 0.37 
 In total 251  137  95  19   
AD Alzheimer’s disease, LBD Lewy body dementia. Statistics presented as n (%) and compared using Kruskal-
Wallis test. *Antidementia is not included 
Polypharmacy was identified in 45% of the patients, while psychotropic 
polypharmacy was identified in seven patients. PIM were identified in 35 patients 
(14%). The top three PIM were long-acting benzodiazepines (n=8, 3.2%), 
combinations with non-steroidal anti-inflammatory drugs (n=7, 2.8%), and 
psychotropic polypharmacy (n=7, 2.8%). Four cases of severe DDI (“should not be 
combined”) were identified, while the majority of DDI were in the group “take 
precautions” (n=149). Here, combinations with beta-blocking agents and 
cholinesterase inhibitors were most frequent (n=23, 9.2%). Use of acetylsalicylic acid 
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in combination with selective serotonin reuptake inhibitors (n=18, 7.2%) and the use 
of bisphosphonates in combination with calcium or drugs combined with calcium 
(n=11, 4.4%) were the second and third most frequent DDI, respectively. There were 
no significant differences in the number of PIM or DDI between the dementia 
diagnoses. 
Factors significantly associated with having PIM were number of prescribed 
medications (odds ratio, OR=1.5, 95% CI 1.3-1.8, p <0.001) and being female 
(OR=2.7, 95% CI 1.1-6.5, p=0.021). While only number of prescribed medications 
(OR=2.0, 95% CI 1.7-2.5, p<0.001) was associated with having DDI. 
4.2 Paper II 
Over 77% of the patients were hospitalized during the five-year study period, and the 
majority were unplanned admissions. Compared to the age-matched general 
population, both AD and LBD had a higher risk of admission (SAR for AD: 
unplanned 1.30, planned 1.35; for LBD: unplanned 1.83, planned 2.01). When 
stratified based on age, patients with LBD in the age group 60-74 years had close to 
four times as many admissions as the general age-matched population. 
Patients with LBD had a significantly shorter time until first hospitalization (median 
1.28 years, 95% CI 0.93-1.67) compared to AD (2.32 years, 95% CI 1.74-3.31). 
Patients with LBD were found to have an increased risk of hospitalization in the 
unadjusted competing risk model (unadjusted SDHR 1.72, 95% CI 1.25-2.35, 
p<0.001). After adjusting for demographic variables and somatic comorbidities 
(SDHR 1.42, 1.01-2.00, p=0.046), and, afterward dementia-related variables (SDHR 
1.37, 0.96, -1.95, p=0.09), the difference in risk was reduced. Adjusting for 
medication-related variables did not substantially affect the SDHR. When death was 
treated as a censoring event, patients with LBD had an 86% higher hazard of being 
hospitalized compared to those with AD in the unadjusted analysis (CSHR 1.86, 95% 
CI 1.35, 2.56, p <0.001). In the fully adjusted model, LBD patients had a 42% higher 
 
hazard, though the difference was no longer significant (CSHR 1.42, 95% CI 0.99, 
2.03, p=0.054). 
Compared to AD, patients with LBD had more unplanned admissions (median 2, IQR 
1-3 vs AD: 1, 0-2, p=0.004) and more unplanned hospital days (median 7 days, IQR 
2-26 vs AD: 2 days, 0-11, p=0.001) for the period of five years after the dementia 
diagnosis. In the unadjusted negative binomial model, LBD patients had 84% more 
hospital days than AD patients (IRR 1.84, 95% CI 1.22-2.77, p=0.004) after five 
years. After adjustment for demographic variables and somatic comorbidities, the 
difference in hospital days between LBD and AD was reduced to 63% (IRR 1.63, 
1.02- 2.61, p=0.040). Further adjustments with dementia-related variables reduced the 
difference even further, and the difference was no longer statistically significant (IRR 
1.53, 0.92, 2.52, p=0.099). When differing observation time were allowed for (due to 
death), the unadjusted IRR for all rates of admission and days in the hospital 
increased. In the fully adjusted model, patients with LBD had a 42% increased risk of 
any hospitalization (IRR 1.42, 1.02, 1.98, p=0.037). 
4.2.1 Additional results 
Hospitalization rate per person-year 
In paper II, results were presented as rate per one year or rate per five years. Death 
was not taken into account. However, in the systematic review from Shepherd et al. 
[84] results were presented per person-year. For purposes of data comparison, 
additional results are presented in table 3. 
Table 3: Mean number of admissions per person-year 
 Alzheimer’s disease  Lewy body dementia 
Person years  769.7  402.6 
 N mean 95% CI  N mean 95% CI 
All hospitalizations 306 0.40 0.35-0.44  248 0.62 0.54-0.70  
Unplanned 267 0.34 0.31-0.38  201 0.50 0.45-0.55  
Planned  39 0.05 0.03-0.07  47 0.12 0.09-0.15  
CI Confidence interval, N Number of admissions 
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4.3 Paper III 
The overall median survival time after diagnosis was 6.2 years (95% CI 5.4-6.9). The 
median survival time after diagnosis for patients with LBD was 4.4 years (95% CI 
3.6-5.2), which was significantly shorter than that for patients with AD (6.9 years, 
95% CI 6.2-7.6, p<0.001). After five years, the survival rates for AD and LBD, were 
68% (95% CI 67.9-68.1) and 34% (95% CI 33.9-34.1), respectively. 
Multivariable Cox regression models showed that older age at diagnosis (hazard ratio, 
HR 1.1, 95% CI 1.0-1.1) and an LBD diagnosis (HR 2.1, 95%CI 1.4-3.3, p<0.001) 
were factors significantly increasing mortality.  
Compared to the age- and sex-matched general population, the study cohort had an 
80% higher risk of dying (SMR=1.8, 95% CI 1.6-2.0). Both AD and LBD were found 
to have higher mortality than the age- and sex-matched general population. The sub-
analyses showed that patients with LBD had SMR=2.6 (95% CI 2.1-3.3), while 
patients with AD had a SMR=1.5 (95% CI 1.3-1.7). In the first year after diagnosis, 
the SMR was close to one indicating that the mortality rate was equal to that of the 
general population. At about two to three years after diagnosis the mortality rate 
increased. 
4.3.1 Additional results 
Use of psychotropic medications  
Paper III reported that pharmaceutical treatments, such as antidementia drugs or the 
use of antipsychotics were not included because very few patients used antidementia 
drugs (n=4) and none of them used antipsychotics. Meanwhile, in paper I, the use of 
antidementia and antipsychotics was reported to be 42% and 8%, respectively. 
Paper III was the first of the three papers to be published. DemVest is an ongoing 
study and a reason for this discrepancy might be that some of the data were not 
plotted or have been updated since the writing of paper III. Additionally, the medical 
data were not adequately registered. Therefore, before analyses related to paper I 
could begin, the database had to be reconstructed so that information about drug use 
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based on ATC could be easily retrieved. Further, the study populations included in 
paper III and I are not exactly the same. Paper III includes only patients from the first 
inclusion period (2005-2007), while paper I includes patients from both inclusion 
periods. This also explains some of the differences in drug treatment between these 
two papers. 
The use of psychotropic drugs was therefore reanalyzed for patients included in paper 
III (table 4). Significantly more patients with AD were treated with antidementia 
drugs, and significantly more patients with LBD were treated with antipsychotics. 
The prescribing practice varied, with three different first-generation antipsychotics 
(levomepromazine n=2, proklorperazin n=2, haloperidol n=5) and three different 
second-generation antipsychotics (risperidone n=1, quetiapine n=1, olanzapine n=1) 
being prescribed. One patient was prescribed lithium. 
 
Table 4: Updated numbers of registered medication used at baseline by 
patients included in paper III. 
 Total AD LBD p-value 
Number of drugs in total 
(median, IQR) 
4 (2; 6) 4 (2; 6) 4 (2; 6) 0.27** 
  N % N % N %  
ATC Psychotropic drugs* 83 43.7 58 42.3 25 47.2 0.66 
N06D Antidementia 78 41.1 66 48.2 12 22.6 0.002 
N06A Antidepressives 58 30.5 43 31.4 15 28.3 0.81 
N05A Antipsychotics 13 6.8 4 3.1 9 16.9 0.002 
N05B Anxiolytics 15 7.9 10 7.3 5 9.4 0.63 




Benzodiazepines 26 13.7 19 13.9 7 13.2 1.00 
 Total  190  137  53   
IQR Interquartile range presented with Q1 and Q3, Statistics presented as n (%) and compared using Pearson 
Chi-Square test unless otherwise noted.  




Predictors of mortality 
To examine the relationship between prescribed medication and mortality, a 
univariate analysis was performed for all medications listed in table 4. Further, a 
multivariable analysis was performed to determine how medications together with 
other baseline covariates were associated with death. In paper III only covariates that 
were significant (p <0.05) in the univariable analysis were included in the 
multivariable model. In this analysis, all covariates with a p <0.25 were included in a 
stepwise multivariable model. Both backward and forward elimination (likelihood 
ratio, LR) were performed, yielding the same result.  
In the univariate model, the use of antidementia drugs was associated with a reduced 
risk of mortality, but was not significant (HR 0.76, 95% CI 0.52-1.12, p=0.17). 
While, the use of antipsychotics was significantly associated with higher mortality 
(HR 2.05, 95% CI 1.12-3.76, p=0.020) in the univariate model. This effect was 
attenuated in the adjusted model and was no longer significant (HR 1.40, 95% CI 
0.70, 2.8, p=0.34). In the fully adjusted model a diagnosis of LBD (HR 1.93, 95% CI 
1.25–3.00, p=0.003), higher age (HR 1.08, 95% CI 1.04–1.11, p<0.001), and being 





This thesis aimed to investigate the medication use and prognosis of patients recently 
diagnosed with mild dementia, with a focus on hospitalization and survival time after 
diagnosis.  
In paper I, medication use at the time of diagnosis was explored with a focus on 
polypharmacy, psychotropic drugs, and adverse drug combinations. This paper 
provides a snapshot of the drug treatment in patients recently diagnosed with 
dementia. This paper does not identify the risks of using psychotropic drugs or of 
polypharmacy. These aspects were included in paper II and in additional results 
related to paper III (section 4.3.1). Papers II and III are longitudinal studies that 
investigate whether one dementia diagnosis is more susceptible to hospitalization or 
death than the other, and compared to the general population, which is relevant to the 
health care providers and the patient and their relatives. 
A critical assessment of the methods applied and how this might have influenced the 
results is provided in the first section (5.2), while a discussion of the results is 
provided in the next section (5.3). The findings will be compared to those of previous 
studies. In addition, similarities and inconsistencies will be discussed, implications 
for practice will be explored, and conclusions will be made if appropriate. 
5.2 Discussion of method 
5.2.1 Validity of the DemVest study 
Strengths 
The DemVest study has been ongoing since 2005 and the majority of the patients 
have been followed until death. The annual follow-up with repeated measurements 
has allowed for persistent and repeated analyses from mild to severe dementia.  
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The study has low attrition for causes other than death. In total 266 patients have 
performed the baseline assessment. Throughout the years, 24 (9.0%) patients have 
withdrawn and three (1.1%) have been excluded due to a lack of information. These 
patients accounted for 10.2% of the total study population. There is a risk of attrition 
bias when patients who have withdrawn from the study differ from those still 
remaining. No significant difference was found in the baseline characteristics 
between patients who withdrew and those who remained in the study, suggesting a 
low risk of attrition bias. However, this project has no knowledge of the patients' 
further disease course. In addition, eight patients were first diagnosed with mild 
dementia, but they did not progress and were diagnosed with mild cognitive 
impairment after five years and excluded. As a result, 87% of the patients are still 
included in the study. 
Since the start of DemVest in 2005, the diagnostic criteria for AD [27] and DLB [16] 
have changed, with the addition of supplementary diagnostics and biomarkers in 
clinical practice. This has led to regular updates of the clinical diagnosis and the three 
papers use different versions of the clinical diagnoses. The last published paper, paper 
II, used the final consensus diagnoses where 56 of them are pathological diagnoses. 
The clinical diagnoses have been found to correlate well with the pathological 
diagnoses [123]. Out of 20 patients with neuropathological verified LBD, 16 had a 
clinical diagnosis of LBD (DLB=11, PDD=5), resulting in a sensitivity, specificity, 
positive predictive value and negative predictive value of 80%, 92%, 84%, and 89%, 
respectively. For a clinical diagnosis of probable AD, the sensitivity, specificity, 
positive predictive value and negative predictive value were 81%, 88%, 89%, and 
79%, respectively [123]. 
Change in recruitment  
Patients were included from outpatient clinics in the counties of Rogaland and 
Hordaland over a period of eight years. During the two first years of the study, all 
patients with a first-time diagnosis of mild dementia were included. After that, only 
patients with DLB or PDD were included in order to increase the number of patients 
with these dementia diagnoses and thereby increase the study’s statistical power and 
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robustness. This change in recruitment could potentially lead to selection bias and 
create two sample groups. However, the recruitment sites and all other selection 
criteria remained unchanged. Further, an analysis of the baseline characteristics from 
the LBD patients included in the two time periods was performed and resulted in the 
detection of no significant differences. Still, this change may cause findings from the 
total dementia group to have a bias effect due to the skewness between AD and LBD, 
with LBD being overrepresented. However, this will probably not affect the findings 
in AD and LBD, individually. 
Representativity and generalizability 
In relation to the representativity of the DemVest cohort, the literature reports the 
proportion of AD and PDD among persons with dementia as being around 50-75% 
and 3-4%, respectively [17, 30] while the proportion of DLB is reported to range 
between 10-24% [15, 29]. The proportion of different forms of dementia in the 
DemVest cohort from the two inclusion periods is seen in figure 4. 
 
 
Figure 4: Frequency of different forms of dementia in the DemVest study 
from the first [3] and second inclusion periods [2]. 
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The first inclusion period from 2005-2007 corresponds relatively well to reported 
proportions. The frequency of AD and DLB was within the reported range, while the 
frequency of PDD patients was slightly above. The proportion of DLB was closer to 
the high end. This may be related to the secondary care often have the ability to 
perform multiple assessments, which in turn enables them to better detect clinical 
differences between diagnoses [29]. Another reason might be these outpatient clinics 
special interest for DLB patients, increasing the likelihood that the characteristic DLB 
features would be detected. However, all patients screened for inclusion were 
consecutive referrals and underwent a comprehensive assessment using established 
diagnostic criteria [120]. In the second inclusion period (after change in the inclusion 
criteria), the proportion of DLB and PDD increased to 31% and 8%, respectively, 
according to plan.  
The DemVest study is based on referrals from general practitioners and is not a 
population-based study. Therefore, the study includes only cases known to the health 
care system. This may lead to a referral bias through the referral of only more 
severely impaired patients with dementia to the outpatient clinics. This applies 
especially to patients with DLB who have a more complex clinical picture, with 
hallucinations, fluctuating cognitions, and REM sleep disturbances. Additionally, 
patients with less severe symptoms might not have been referred if the symptoms of 
dementia did not lead to severe enough stress for the patients or caregiver to seek 
help. However, general practitioners were asked to refer patients with possible 
dementia even if this might not have been required for medical reasons.  
Mild dementia was defined as having an MMSE score of 20 or above or a CDR of 1 
or lower. According to Monroe et al., the level of education, language, hearing and 
vision abilities should be taken into account before using the MMSE to prevent the 
MMSE score from being biased. Failure to do so may potentially lead to lower 
MMSE score [133]. In DemVest, all patients were ethnic Norwegians and the median 
level of education was nine years for both AD and LBD. Some patients probably had 
impaired vision and/or hearing, but this was likely compensated for by the use of 
glasses or hearing aids. Therefore, the assumptions are assumed to have been met. 
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Further, the MMSE has been criticized for not being able to sufficiently detect the 
cognitive impairment in DLB as it does not directly assess psychiatric, autonomic, or 
executive functions that often are impaired in these patients [134] and for showing 
unsatisfactory results in terms of diagnosing patients with PDD [135]. In addition, the 
same MMSE score might not represent the same disease severity for patients with 
DLB as compared to patients with AD [134], potentially causing a recruitment bias. 
Although, there were no significant differences in the CDR at baseline. The CDR 
captures a broader range of functional deficits due to cognition and may be a more 
precise and comprehensive measure of dementia severity in LBD. However, the CDR 
was also designed for use in AD and has not yet been sufficiently tested in DLB [75]. 
Statistical analysis  
DemVest has one of the largest LBD cohorts followed longitudinally in a single 
study. Still, the number of patients was relatively low and, thus the statistical power 
to detect significant associations may be limited. As the statistical power and the risk 
of type II errors are related, studies with low power have a higher risk of making a 
type II error [136]. Therefore, the recruitment was changed in 2007 to increase the 
sample size of LBD and thereby the statistical power. 
In this project several statistical tests have been performed, which increases the risk 
of at least one test yielding a false significant result, thereby causing a type I error. To 
reduce the risk of incorrect conclusions, adjustments for multiple testing can be 
applied [137]. However, there is no clear-cut when to adjust for multiple testing, as 
this depends on the study performed. In confirmatory studies adjustments for multiple 
testing should be applied, while adjustment for multiple testing in explorative studies 
can cause type II errors [137]. The papers included in this project have reported more 
preliminary results and are believed to be more akin to exploratory studies than 
confirmatory studies. Therefore, multiple testing was considered not to be necessary 
for this project. 
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5.2.2 Combining DLB and PDD 
In this thesis, DLB and PDD were combined and collectively referred to as LBD. A 
relevant topic is whether this is justified. 
They are both defined as alpha-synuclein disorders and are considered part of the 
LBD spectrum [15]. DLB and PDD differ in the sequence of the onset of dementia 
and Parkinsonism and possibly levodopa-responsiveness [16], though they share 
many clinical and neuropathological features [43]. So far, no specific clinical and 
pathological differences between DLB and PDD have been identified, and as the 
diseases progress, distinguishing between them becomes difficult [15]. Therefore, 
DLB and PDD are believed to be related alpha-synucleinopathies with different 
phenotypic presentations, which are unlikely to affect prognosis and clinical 
outcomes [138]. In addition, several studies report no statistically significant 
difference in mortality between the two entities [138, 139]. 
5.2.3 Choice of index date 
Choice of index date differs from study to study in the existing literature. Some 
studies have used time from first symptom as the index date [140], while others [138, 
141], including this project, have applied date of diagnosis as the index date. 
Different factors may affect time to diagnosis. Higher education has been found to 
increase time from symptom onset to diagnosis, regardless of dementia diagnosis 
[142]. Data from a register study found that five additional years of education 
increased the time to diagnosis by 10%, but it was not possible to distinguish this 
effect between different forms of dementia due to low statistical power [142]. 
Moreover, it might take up to a year after help is sought before a DLB diagnosis is 
made. Patients with DLB may also have received other diagnoses before being 
diagnosed with dementia [143]. Findings from DemVest showed that patients with 
LBD reported a significantly longer time from first symptom to diagnosis compared 
to patients with AD (three years vs two years). This delay from first symptom to 
diagnosis may be related to the complex clinical phenotype of LBD with 
Parkinsonism, hallucinations, fluctuations and sleeping disorders [15]. This time 
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difference may have led to more patients with LBD being assessed closer to the time 
of the study outcome, e.g., first hospitalization or death. Additionally, there is still 
stigma attached to dementia, which may prevent people from seeking help [8]. This 
may cause patients to die before being diagnosed with dementia, resulting in an 
underestimation of the true prognosis. Further, the timing of the first symptom also 
depends on various factors. First, it is affected by the patient’s or caregiver’s ability 
to remember. In addition, the time is influenced by their knowledge about dementia 
and the symptoms related to the disease [96]. Some may even believe the first 
symptoms to be part of the normal aging process. Using the time from diagnosis as 
the index date was therefore considered the best choice for assessing prognosis. 
5.2.4 Information about drug treatment and medication adherence 
Information about drug treatment was retrieved from the patient or family members 
and was either given orally or based on a written medication list. Information about 
over-the-counter drugs could not be retrieved. Norway has a relatively strict policy 
governing which medications can be sold over the counter and outside of the 
pharmacy. However, non-prescription drugs might be considered inappropriate for 
some patients.  
This project has no information related to medication adherence. Patients with 
Parkinson’s disease often have complex medication regimes, with multiple doses in 
one day. This complex medication regimen may be difficult to adhere to as the 
disease progresses. Further, patients with dementia often experience reduced 
communication skills as the disease progresses [13], which may be why a study 
reported people with cognitive impairment to report fewer adverse events than people 
with normal cognition. [144]. In addition, interpreting clinical signs and symptoms 
related to drug treatment may be difficult when communication skills reduces. 
5.2.5 Choice of screening tool for identifying PIM 
The NorGeP criteria were applied to assess the prevalence of PIM in paper I. This 
screening tool consists of 21 single drugs and 15 drug-drug combinations that should 
be avoided in people above 70 years. It was developed and validated through a three-
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round Delphi process [6]. Initially, it was considered to use the second version of the 
STOP criteria [110]. However, the DemVest study was not initiated to assess medical 
treatment in patients with dementia and the choice of screening tool had to be based 
on the information available. Many of the STOPP criteria depend on clinical 
information, which was not available. This would have led to only parts of the 
STOPP criteria being applicable. The NorGeP criteria were considered the most 
optimal choice of screening tool as it was developed in Norway and require no 
clinical information to be applied. 
The prevalence of PIM was fairly low in this project (14%); a higher prevalence 
might have been found if another screening tool had been applied. Some screening 
tools include medication that should not be used with specific diseases [109, 110], 
which the NorGeP criteria does not. This may result in an underestimation of the 
prevalence of PIM. The prevalence of PIM shows great diversity between different 
screening tools applied to the same population and there is little correlation across 
these scoring tools [145]. This implies that more consensus is needed regarding 
which drugs should be defined as PIM, so that more uniform screening tools can be 
developed. This would potentially lead to more comparable studies. 
The NorGeP criteria have been developed to assess PIM in people above 70 years of 
age. In paper I, the median age at baseline was 77 years (IQR 71-81), although, some 
patients were younger than 70 years. The pathological changes in the brain due to 
dementia make patients with dementia more sensitive to specific drugs such as 
antipsychotics and drugs with anticholinergic properties [146] and thereby more 
prone to adverse events. Hence, assessing PIM in patients with dementia who are 
younger than 70 years may improve drug regimens and reducing the risk of adverse 
drug events. 
When assessing appropriate medication use, several aspects should be considered. 
Most early screening tools focused on specific drugs, dosages, and duration. 
However, other aspects, such as the omission of medications, medication monitoring, 
and drug-disease interactions, should also be considered. During the last decade, both 
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STOPP and Beer’s criteria have been updated and now evaluate more aspects than 
the original versions (see table 5). The NorGeP criteria evaluate the fewest aspects 
and have not been updated since their publication in 2009, though a nursing home 
version was published in 2015 [147]. 
Table 5: Aspects evaluated in different potentially inappropriate 
medications screening tools. Modified from Motter et al. [108]. 
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The use of screening tools to detect PIM may be relevant to assessing the quality of 
prescribing and to informing authorities, stakeholders and researchers. Still, many of 
the screening tools are comprehensive and may be difficult to use at the clinical level 
[148]. If applying a screening tool, one should choose a tool that, in addition to PIM 
also identifies drugs that should have been used to increase the clinical impact [149]. 
If it had been possible, it would have been preferable to perform an advanced 
medication review [150]. This method includes medication history, clinical 
information and the patient perspective, which is important when considering 
appropriate drug treatment. 
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5.3 Discussion of results 
5.3.1 Appropriate drug treatment 
This section aims to place the drug treatment in context and compare the findings 
with others. The best treatment available at the time of diagnosis, in relation to the 
specific dementia diagnosis, was given to patients in DemVest. However, this study 
was not originally designed to assess appropriate drug treatment; strengths and 
limitations related to that will also be discussed. 
Polypharmacy and use of psychotropic drugs 
The prevalence of polypharmacy in patients with dementia has been found to range 
from 25-98%, depending on the setting [149]. The prevalence of polypharmacy was 
45% in the DemVest cohort at baseline. The PRIME study, a multicenter, prospective 
study including patients with mild cognitive impairment and dementia, reported that 
66% of the study participants were exposed to polypharmacy [151]. These findings 
are somewhat higher than those found in DemVest. Meanwhile a register study from 
Denmark reported that the prevalence of polypharmacy in community-dwelling 
people with dementia was 54.5% [103], which is more in line with the findings in 
DemVest. Overall, the prevalence of polypharmacy is high in patients with dementia 
living in community settings. Improving polypharmacy in patients with dementia and 
multimorbidity may be challenging, but the use of screening tools along with clinical 
information may lead to more appropriate polypharmacy, especially if possible 
prescribing omissions are considered [116]. 
The use of psychotropic drugs in DemVest is generally in line with the use reported 
in the population-based Cache County Study [152], except for the use of antidementia 
drugs and benzodiazepines. In DemVest, the use of benzodiazepines was nearly twice 
as high (16% vs 7.4%), while use of antidementia drugs was nearly three times as 
high (42% vs 15%). The low use of antidementia drugs in the Cache County study is 
probably related to Donepezil first being approved for medical use in the United 
States in 1996 [153]. This was one year after the establishment of the Cache County 
Study. Some of the differences in the use of benzodiazepines may be attributed to 
 
how benzodiazepines are grouped. In this project, benzodiazepines consist of 
medications from the following ATC-groups: N05BA, N05CD, and N05CF. 
However, the Cache County Study does not state how the benzodiazepines were 
grouped. The PRIME study reported the use of antipsychotics, benzodiazepines and 
antidementia drugs at baseline to be 25%, 21%, and 62%, respectively [73, 154]. The 
use of antipsychotics and benzodiazepines was higher compared to DemVest, though 
the PRIME study reported benzodiazepines only from the ATC group N05BA. The 
use of antidementia drugs in the PRIME study was in line with the use at follow-up 1 
(61%) in DemVest [24]. Compared to DemVest, a study of patients with dementia 
receiving domiciliary care in Norway [155], reported less use of antidementia drugs 
(13% vs 42%) and antidepressants (20% vs 32%). The low use of antidementia drugs 
in that study may be explained by the fact that the majority of patients with dementia 
(80%) were diagnosed after inclusion [155]. 
Prevalence of PIM and DDI 
When analyses for paper I were executed, no other papers investigating the 
prevalence of PIM in home-dwelling patients with mild dementia were found. 
Therefore, the prevalence of PIM was compared to study samples in which the 
patients were in different stages of their disease, or in which the study was conducted 
in a different setting [156, 157]. Later, one systematic review from 2015 was found 
[158]. This systematic review examined the prevalence of PIM in people with 
cognitive impairment and dementia in different settings. Eight of these studies 
included people with dementia living in the community [158]. The prevalence of PIM 
in these eight ranged between 10-56%. Since then, at least three other reviews 
assessing inappropriate medications in people with dementia have been published. 
These reviews report that the prevalence of PIM ranges from 14-74% [86, 149, 159]. 
The systematic review by Patel et al., included seven studies, consisting only of 
ambulatory home-dwelling people with dementia [159]. Four different tools were 
applied to detect PIM, none of them applied the NorGeP criteria. This systematic 
review reported the most narrow range of PIM, ranging from 15% to almost 47%, 
with a median PIM of 26% [159]. The review was published in 2017 but did not 
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include papers published after 2015. Since then, a minimum of four additional studies 
including outpatients with dementia have been published [103, 151, 160, 161] 
reporting a prevalence of PIM ranging from 21-64%. Correspondingly, the 
prevalence of PIM in paper I is at the lowest end (14%). The findings of few PIM 
may be because patients in DemVest were in their early stages of dementia and were 
not using many medications, tough it is most likely due to the selection of screening 
tool as discussed in section 5.2.5. 
There are conflicting results as to whether patients with dementia have higher 
prevalence of PIM compared to patients without dementia [149]. Some studies report 
the prevalence to be higher in patients with dementia [92, 103], while other studies 
report the prevalence of PIM to be higher in patients without dementia [162, 163]. 
Additionally, some studies report no difference between these two groups [144]. This 
inconsistency may be explained by differences in study design and the use of 
different screening tools [149]. Therefore it would have been preferable to apply the 
NorGeP criteria to a comparison group to be able to more explicitly state whether the 
prevalence in DemVest was low or high. 
Benzodiazepines, and anticholinergic drugs are among the most commonly reported 
PIM [149]. These drugs may cause cognitive and psychical impairment in patients 
with dementia [146, 164]. The NorGeP criteria also consider benzodiazepines as a 
PIM and although they do not specifically indicate anticholinergic drugs, the NorGeP 
criteria contain drugs with anticholinergic properties such as tricyclic antidepressants 
and first- generation antihistamines. In line with recent findings, benzodiazepines 
were the most frequent PIM (n=8) in this project, while four anticholinergic drugs 
were identified. The prevalence of anticholinergic drugs would probably have been 
higher if an explicit anticholinergic assessment tool had been applied, but this was 
beyond the scope of this project. 
Paper I reported no difference in PIM use between AD and DLB, and an additional 
analysis (data not published) showed no difference between patients with AD and 
LBD. However, a study including more than 2000 patients with AD and 144 patients 
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with LBD reported that patients with LBD had significantly more PIM than patients 
with AD [165]. The patients with LBD used more medications compared to AD, 
which is a risk factor for having PIM. Meanwhile, the difference may also be 
explained by the choice of screening tool. They applied the Beer’s Criteria from 2015 
which evaluates more aspects than the NorGeP Criteria (see table 5, section 5.2.5).  
A study from Germany reported that the prevalence of DDI in community-dwelling 
patients with dementia was 35% [166], which is in line with the prevalence of “take 
precaution” DDI reported in paper I (36%). A Swedish hospital study including 
patients with dementia, reported that the prevalence of clinically identified DDI to be 
43% [167]. The overall findings are comparable with findings in paper I. However, a 
higher frequency of DDI that should be avoided (7.6%) was reported [167]. The 
patients included in the Swedish study used more medication compared to patients in 
DemVest, which may explain some of the differences. Another potential reason may 
be that the interaction database used ranks interactions differently than the one used 
in Paper I. 
In paper I, the prevalence of DDI in the group “take precaution” was relatively high 
(36%), but the study had no knowledge of whether dose adjustments already had been 
made for this group of interactions. If this has not been done, this may be an area for 
future improvement. In addition, there is a possibility that patients might have had 
other interactions that have not been identified. Paper I addressed only DDI, but a 
drug interaction can also be related to other factors, such as food or other diseases. 
Therefore, this project analyzed just some of all potential drug interactions. 
The assessed medication were prescribed between 2005 and 2013 and there is a 
possibility that the patterns of drug prescribing in Norway might have changed since 
then. Halvorsen et al. [168] analyzed the trends in prescribed PIM in different 
Norwegian nursing homes at three different time periods (1997, 2005, and 2011). 
They applied the nursing home version of the NorGeP criteria [147] and found that 
the prescribing of several PIM was reduced. However, the overall use of PIM 
increased in this period, indicating a shift in prescribing pattern [168]. Although the 
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study is from a setting found to have higher risk of being prescribed PIM [148], the 
potential change in prescribing patterns may also have taken place among outpatients. 
Factors associated with PIM or DDI 
In paper I, the female gender was associated with having PIM. This finding is in line 
with others studies [144, 156, 161]. However, the reasons why the female gender is 
associated with an increased risk of having PIM are however not known. Lau et al. 
[163] suggested that the use of estrogen may be a possible reason. They performed 
additional analyses that removed estrogen, which resulted in no significant difference 
between men and women [163]. However, the NorGeP criteria do not list estrogen as 
PIM; therefore, estrogen is not a plausible explanation for this study. Patel et al. 
[159], suggested that association of the female gender with PIM may be related to 
women having more complaints related to depression, sleeplessness, and 
nervousness, which may increase their risk of being prescribed psychotropic drugs 
such as benzodiazepines and antidepressants. The association between an increased 
number of drugs used and having PIM and DDI was not surprising, and is in line with 
other studies including outpatients with dementia [144, 156, 161, 167]. Another study 
including patients with suspicion of dementia reported that the use of a medication 
dispenser or the receipt of support with drug administration had a positive effect and 
reduced the risk of PIM (OR 0.13, 95% CI 0.02, 0.63) [144]. However, information 
about this was not available in this project. 
5.3.2 Hospitalization 
Compared to the general population  
In paper II, SAR was calculated to compare the hospitalization rate in AD and LBD 
with the age-matched general population from the catchment area. SAR revealed a 
higher rate of admissions, for both planned and unplanned admissions in patients with 
AD and LBD (Planned: AD 1.35, LBD 2.01; Unplanned: AD 1.30, LBD 1.83). These 
findings are in the same direction as the meta-analysis in Shepherd et al. [84]. 
Adjusted for age, sex, and physical comorbidity, the meta-analysis gave a pooled 
relative risk of 1.42 (95% CI 1.21, 1.66) for people with dementia compared to those 
without [84]. 
 
When SAR was divided into age-groups, patients between 60-74 years with LBD had 
almost four times as many hospitalizations during the first year after diagnosis 
compared to the general age-matched population. Unfortunately, it was not possible 
to adjust for sex due to the small sample size. Only admissions that took place during 
the first 12 months after diagnosis were included in the calculation of SAR. This was 
done to reduce the competing risk of death. This resulted in a small number of 
admissions, which may have reduced the strength of the results. Therefore, these 
results may be regarded as preliminary; several studies with a larger study sample 
must be conducted before a reliable conclusion can be made. 
Differences between patients with AD and LBD 
In 2019, the first systematic review reporting on the hospitalization rate in patients 
with dementia was published [84]. Close to 280,000 patients with dementia were 
included, but just 194 of the patients had LBD [90]. The reported hospitalization rate 
ranged between 0.37 and 1.26 per person-year [84]. The findings from the additional 
analysis (see section 4.2.1) show that findings from paper II is at the lower end, with 
a hospitalization rate per person-year of 0.40 (95%CI 0.35-0.44) and 0.62 (95%CI 
0.54-0.70) for patients with AD and LBD, respectively. 
In paper II, patients with LBD were found to have a shorter time until first 
hospitalization, more admissions, and more unplanned hospital days compared to 
patients with AD. Other studies report findings in the same direction [81, 90, 91], 
except for one [78]. These consistent findings indicate that patients with LBD have a 
poorer prognosis in relation to hospitalization compared to patients with AD. 
Factors affecting hospitalization  
There is strong evidence that older age affects hospitalization and moderate evidence 
that physical comorbidity is associated with hospitalizations [84]. This is consistent 
with findings from paper II showing a reduced SDHR and CSHR after adjustment for 
these factors. Further, there is moderate evidence that taking seven or more 
medications is associated with hospitalization [84]. In paper II, adjustments for 
having polypharmacy did not affect the size of SDHR and CSHR. An explanation for 
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this may be that polypharmacy, defined as the use of five or more medications is not 
sufficient to find any association. 
Polypharmacy and the use of psychotropic drugs were based on drugs used during the 
first year; changes in drug regimens were not taken into consideration during the 
study period and there is a possibility that the drug regimen changed during the 
follow-up. Further, other drugs than those adjusted for in paper II may be associated 
with hospitalization. Beta-blockers in combination with other medications were the 
most frequently reported DDI in Paper I, and it is suspected that use of such drugs 
may be the underlying cause in many hospitalizations [169]. The use of 
benzodiazepines has been found to increase the risk of hip fracture among patients 
with AD [170], which again, leads to hospitalization. None of these drugs were 
included in the statistical model although it would have been interesting to have 
analyzed whether and how they were associated with hospitalization. Still, no 
substantial change was seen on the effect size (SDHR, CSHR) after adjustment for 
other psychotropic drugs and polypharmacy. More studies are needed to clarify 
whether the reduction of polypharmacy, psychotropic drugs or PIM is effective in 
reducing adverse events and thereby potentially preventing hospitalization. 
During the five-year study period, patients with LBD spent more time in the hospital 
compared to patients with AD and the IRR ranged from 1.41 to 1.84 in unadjusted 
analysis, depending on the outcome. When counting days in hospital, patients with 
LBD had 53% (IRR 1.53, 95% CI 0.92-2.52) more days in hospital compared to AD, 
in the fully adjusted negative binomial model but was no longer statistically 
significant. This may indicate that something else have an impact on hospitalization. 
Functional impairment shows moderate evidence of being associated with 
hospitalization [84]. Unfortunately, it was not possible to adjust for functional 
impairment in paper II. Adjusting for functional impairment would have strengthened 
the study and could potentially explain some of the increased effect size seen in 
patients with LBD. The statistical model was arranged to compare rate and risk 
between LBD and AD. Therefore it is not possible to disentangle the specific variable 
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effect from each other. To gain knowledge about whether and how specific factors 
affect hospitalization another set-up should have been chosen 
Knowledge about the cause of admission is relevant and may lead to more targeted 
care, and interventions aiming at reducing these causes may potentially prevent some 
of the hospitalizations. In patients with AD, frequent causes of admissions have been 
reported to be related to falls and fall-related injuries, cardiac disease, gastrointestinal 
system and pneumonia [171]. While, patients with LBD have been reported to be 
admitted due to neuropsychiatric symptoms, falls and infections [89]. Paper II did not 
highlight the causes of admission, but falls and fall-related injuries composed the 
most frequent cause of admission for both dementia diagnoses in DemVest (data not 
published). Therefore, capturing early signs of infections or those at risk of functional 
impairment and thereby reducing the risk of falling may prevent hospitalizations. 
5.3.3 Survival and mortality  
Compared to the general population 
In paper III, SMR was calculated to compare mortality in AD and LBD with the age- 
and sex-matched general population in Norway. Patients with LBD were found to 
have a mortality rate of 2.6 (SMR 2.6, 95% CI 2.1-3.3), while patients with AD had a 
mortality rate of 1.5 (SMR 1.5, 95% CI 1.3-1.7) compared to the general population. 
A study from the US [172], published in 2010, reported similar findings for patients 
with LBD (SMR 2.42) and AD (SMRprobable AD 1.70, SMRpossible AD 1.84). The 
findings from this study and paper III were further confirmed by Larsson et al. [139] 
and Strand et al. [141]. Both report that patients with dementia have higher mortality 
than the general population. Savica et al. [173] analyzed survival curves in different 
synucleinopathies. All the synucleinopathies had increased mortality compared to the 
general population and the difference diverged from the general population 
approximately two years after diagnosis [173], which are in line with the SMR over 
time found in paper III. This suggests that, around two years after the dementia 
diagnosis, something changes that causes the mortality to deviate from the 
comparison group. The cause of this is not known and should be further explored. 
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Differences between patients with AD and LBD  
Paper III was one of the first published studies on mortality in patients with LBD 
using the DLB diagnostic criteria from 2005. The main findings were that patients 
with dementia had higher mortality compared to the general population. Patients with 
LBD had a significantly shorter survival time than patients with AD, while higher age 
at baseline and having LBD predicted higher mortality in dementia. 
The introduction of the consensus criteria for the diagnosis of DLB in 1996 [36] and 
the further revision in 2005 [39] which increased the sensitivity of the consensus 
criteria [174] have probably led to more patient being diagnosed with DLB resulting 
in larger studies with DLB patients. Additionally, naturalistic data from electronic 
health records may now be retrieved, which, again, has led to an increasing number 
of publications on survival in DLB [140]. As a result, the first systematic review and 
meta-analysis comparing survival in patients with AD and DLB was published in 
2019 [95]. Eleven papers were included, including paper III. The baseline 
characteristics in the meta-analysis are not entirely the same as those reported in 
paper III as the meta-analysis only included patients with DLB. 
The systematic review comprised 20,923 patients with AD and 2029 patients with 
DLB. The average survival time for AD and DLB was reported to be 5.66 years 
(SD±5.32) and 4.1 years (SD±4.10), respectively [95]. A recently published study 
from a memory clinic in Sweden comparing mortality in LBD with that of the general 
population, reported a median survival time of 4.1 years (IQR 2.6-6.0) [139], while a 
Norwegian registry-based prospective study, NorCog, reported that patients with AD 
have a significantly longer survival time after diagnosis than patient with LBD [141]. 
Thus, the findings from paper III are very much in line with the most recent published 
literature. These studies increase the evidence that patients with LBD have a shorter 
survival time after diagnosis compared to patients with AD. However, the confidence 
interval in the Swedish study has a substantial range and the survival time reported in 
the meta-analysis ranged from 1.9 to 5.59 years for DLB patients and 2.29 to 8.3 
years for AD patients. Hence, there is still a too-pronounced variation in the reported 
survival time to be able to provide a precise estimate of survival time to health care 
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personnel and patients. These heterogeneous results may be due to differences in the 
choice of index date (see section 5.2.3) or the inclusion of patients at different stages 
of their dementia. 
Factors predicting mortality in dementia 
Paper III found that higher age at baseline was a predicting factor for increased 
mortality, which is in line with published literature. The findings of LBD having 
increased mortality compared to AD have recently been confirmed in another 
Norwegian study. Strand et al. [141], reported that patients with LBD have a 71% 
(HR 1.71, 95% CI 1.33-2.21) higher risk of death than patients with AD, even after 
adjustment for age, gender, comorbidity, functional impairment, and cognition [141]. 
The additional finding (section 4.3.1) of the male gender influencing mortality is in 
line with previous findings [175]. However, Strand et al. [141] found a gender 
difference only in patients with AD and not in patients with LBD. Most studies have 
reported on observed mortality and not on life expectancy and the years of life lost, 
which Strand et al. did [141]. They found that both men and women with dementia 
had a significantly shorter life expectancy, but women with dementia had 
significantly more years of life lost than men with dementia when compared to the 
general population. According to Strand et al., this was believed to be related to the 
fact that women, in general, live longer and thus lose more years of life [141].  
Further established predictors of mortality in dementia are disease severity, 
comorbidities, and functional impairment [175]. The first two predictors were 
significantly associated with higher mortality in the univariable analysis in paper III, 
but did not remain significant in the fully adjusted model. Adjustment for functional 
impairment was not possible, although it would have been interesting to see how 
functional impairment was related to mortality as patients with DLB have been 
reported to have more functional impairment than AD patients at baseline [176], but 
with no significant difference in rate of functional decline during follow-up [177]. 
In relation to psychotropic drugs, the use of antidementia drugs indicated lower risk 
of mortality, but was not statistically significant (see section 4.3.1). Two other studies 
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reported that the use of cholinesterase inhibitors reduced the risk of mortality in 
patients with AD [178, 179]. Studies including patients with LBD have not been 
found, but a positive clinical response to memantine revealed a positive effect on 
survival time for patients with LBD [180]. The use of antipsychotics is recognized as 
a predictor of increased mortality [181]. However, this association was not 
established in this project (see section 4.3.1), nor was it established in a more recent, 
larger study [140]. Overall, studies report that LBD is associated with increased 
mortality compared to AD even after adjustment for relevant predictors. This 
suggests that other factors related to survival still are unknown.
 
6. Conclusions and clinical implications 
The general aim of this thesis was to increase knowledge about pharmacological 
treatment and prognosis related to hospitalization and mortality in patients recently 
diagnosed with AD and LBD. 
The increased risk of hospitalization, even in mild dementia, should be highlighted. 
Falls and fall-related injuries seem to be major causes of admission among patients 
with AD and LBD - causes that are potentially preventable. The reduced survival and 
higher mortality, which cause a substantial years of life lost should also be 
emphasized. However, the large range of survival time makes it difficult to inform 
about individual prognosis. The quality of prescribing seems to be acceptable in 
relation to PIM and DDI, tough clinicians are encouraged to have a regular focus on 
appropriate drug use. 
A dementia diagnosis often leads to symptomatic treatment, mapping of the 
functional level and the need for help, which, in turn, may reduce the risk of 
hospitalization and longer survival time. Therefore, a timely and correct diagnosis of 
dementia may provide optimal care and hopefully improve prognosis in patients with 
dementia. 
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7. Future research 
Several studies have initiated interventions to reduce PIM and optimize the 
pharmacological treatment [182, 183]. Due to the naturalistic design of this project, 
no intervention was performed. Interventions such as medication reviews, use of 
computerized systems, or interventions related to education or deprescribing have 
shown positive results in reducing the number of PIM [183]. In a recent systematic 
Cochrane review, two thirds of the studies examined how interventions, focusing on 
appropriate polypharmacy, were associated with clinical outcomes related to 
hospitalization or quality of life. None of them included mortality [182]. Due to 
design limitations in the included studies, the Cochrane systematic review concluded 
that there is little evidence of whether interventions focusing on appropriate use of 
polypharmacy are effective [182]. All the included studies reported outcomes using a 
quantitative measure. This may not be sufficient to detect an effect regarding 
appropriate drug treatment. Qualitative methods explore other aspects than 
quantitative methods do, and may be used to get a deeper insight into, and 
understanding of, the patients’ experience after an intervention. Therefore, combining 
these methods in future studies may complement the findings and increase evidence. 
Patients with dementia, and especially patients with LBD were found to have a high 
admission rate compared to the general population. Admissions related to falls and 
fall-related injuries and infections (see section 5.3.2) are frequent in patients with 
dementia [90, 171], and represent a potentially preventable cause. Future studies 
should focus on how to identify patients who are at risk of infections or falls. 
Reducing such hospitalizations may lead to a better quality of life for the patient and 
reduce health care costs. Further, not all hospitalizations are preventable. Therefore, 
one should investigate how to reduce unnecessary stress and optimize care for 
patients with dementia who are hospitalized. Other patient groups such as patients 
with transient ischemic attack (TIA) or cardiac arrest, have specific treatment loops. 
A treatment loop specifically aimed at patients with dementia or cognitive 
impairment may be beneficial for reducing stress at admission. 
 
Currently, there is little knowledge about drug use prior to nursing home admission in 
patients with dementia in Norway. A planned PhD project will combine data from 
several central health registers. An important focus of this project will be how 
psychotropic drug use, and potentially PIM, are associated with institutionalization or 
death in patients with dementia. 
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Objectives: The objectives of this study were to describe the use of psychotropic drugs among home-
dwelling people with mild dementia, to identify potentially inappropriate medications (PIM) and
drug–drug interactions (DDI), and to analyze potential variables associated with having PIM and DDI.
Methods: Patients (n=251) with a first-time diagnosis of mild dementia (defined as a mini-mental state
examination score >20) were included from outpatient clinics. Prevalence of psychotropic drug use,
polypharmacy, and psychotropic polypharmacy were investigated. The prevalence of PIM and DDI
were defined using the Norwegian general practice criteria and an interactions database, respectively.
Variables associated with having PIM and DDI were assessed using a multivariable logistic regression
analysis adjusting for relevant demographic and clinical variables.
Results:Almost 96% of the patients used one or more medications. Polypharmacy was found in 45% of
the patients, and nearly 70% of the patients were using one or more psychotropic drugs. Psychotropic
polypharmacy was found in seven patients. PIM were identified in 35 patients (14%), while only four
severe DDI were found. Female sex and number of medications were significantly associated with
having PIM, whereas only number of medications was significantly associated with having DDI.
Conclusion: Few patients had PIM or severe DDI, indicating that the quality of prescribing was acceptable.
However, psychotropic drug use was common in home-dwelling people with mild dementia despite
limited evidence of benefit in dementia. More knowledge is needed about the potential risks associated
with psychotropic drug use and having PIM and DDI in people with mild dementia. Copyright# 2016
John Wiley & Sons, Ltd.
Key words: dementia; psychotropic medications; drug interactions; drug therapy; outpatients; potentially inappropriate
medications




Older people are major consumers of prescription
medicine (Norwegian Institute of Public Health, 2014),
with increased risk of polypharmacy and drug–drug
interactions (DDI). This, in combination with decreased
drug tolerance due to age-related changes in the
pharmacokinetics and pharmacodynamics, leads the
older people to being at high risk of having drug-related
problems (Lau et al., 2010). Dementia is one of the most
common age-related disorders, and the disease increases
the risk of adverse drug reactions (Hajjar et al., 2003).
Neuropsychiatric symptoms such as aggression, agita-
tion, sleep disturbances, and hallucinations are frequent
Copyright # 2016 John Wiley & Sons, Ltd. Int J Geriatr Psychiatry 2016
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in dementia, and psychotropic drugs such as benzodiaz-
epines and antipsychotics are often used (Hartikainen
et al., 2003; Wergeland et al., 2014), despite limited evi-
dence of benefit and high risk for adverse effects
(Defrancesco et al., 2015; Schneider et al., 2005).
High drug consumption was found to be a strong pre-
dictor of institutionalization (Luppa et al., 2010), and one
of five prescriptions to older community-dwelling people
has been found to be inappropriate (Opondo et al.,
2012). Therefore, older people may benefit from a drug
assessment to reduce the number of drugs and especially
potentially inappropriate medications (PIM). Screening
tools like “the Norwegian general practice” (NORGEP)
criteria (Rognstad et al., 2009), “screening tool of
older persons’ potentially inappropriate prescrip-
tions” (O’Mahony et al., 2015), and “Beers criteria
for PIM use in older adults” (The American Geriat-
rics Society, 2012) may be used to assess PIM.
Studies investigating the prevalence of PIM in
people with dementia are mostly based on patients
living in care homes or nursing homes (Bakken
et al., 2012; Parsons et al., 2012). The few studies in
home-dwelling people with dementia included a
combination of home-dwelling and institutionalized
patients or patients with different degrees of dementia
(Andersen et al., 2011; Lau et al., 2010; Montastruc
et al., 2013). Considering the increasing number of
people with dementia, with about 50% of them living
at home (Hjort and Waaler, 2010), more studies per-
formed in this group are needed. The objectives of this
study were to describe the use of psychotropic drugs
among home-dwelling people with mild dementia, to
identify PIM and DDI, and to analyze potential
variables associated with having PIM and DDI.
Methods
Material
This is a cross-sectional study based on a longitudinal
cohort on dementia in western Norway, the DemWest
study, (Aarsland et al., 2008). From March 2005 to
March 2007, home-dwelling patients with a first-time
diagnosis of mild dementia (defined as a mini-mental
state examination (Folstein et al., 1975) score >20)
were consecutively included from geriatric and
psychogeriatric outpatient clinics in the counties of
Hordaland and Rogaland, Norway. From April 2007
to April 2013, only patients with Parkinson’s disease
with dementia and dementia with Lewy bodies
(DLB) were included. Patients without dementia,
terminal illness, or with previous history of any
psychiatric disorder were excluded. Of the 266 patients
included in the study, 15 patients were excluded
because of different reasons (missing information
about diagnosis (n=8), mild cognitive impairment
(n=4), and moderate dementia (n=3)). The study
sample therefore consisted of 251 patients, all of whom
had available information about drug use.
Ethical issues
The study was approved by the regional committee for
medical and health research ethics, REC West. After
the study procedure had been explained in detail, written
consent to participate was provided by the subjects or
next of kin if the patient was unable to consent
Diagnosis and assessment
The diagnosis of dementia was made according to the
Diagnostic and Statistical Manual for Mental Disorders,
4th edition (DSM-IV) and classification of dementia
according to consensus criteria (Emre et al., 2007;
McKeith et al., 2005; McKhann et al., 1984). For a
thorough description of the case finding, diagnostic
criteria, and diagnostic procedures, please see the work
of Aarsland et al. (2008). All patients were examined at
baseline, and demographic and clinical data were
recorded. The diagnosis was re-evaluated during the
clinical follow-up, and the final diagnosis was made as
a consensus between two experts in geriatric psychiatry
and one geriatrician, with pathological verification in
35 of the patients, at the time of writing. Baseline
examinations included the following instruments: the
mini-mental state examination (Folstein et al., 1975)
and the Clinical Dementia Rating Scale (CDR) (Morris,
1997), which were used to measure the cognitive decline.
The CDR assesses the impairment in six categories
where memory is weighted highest. The global score of
CDR was calculated using an online algorithm (National
Alzheimer’s Coordinating Center, 2014). A global score
of 0 corresponds to no dementia, 0.5 to very mild
dementia, 1 to mild dementia, 2 to moderate dementia,
and 3 to severe dementia. The total burden of medical
illness was quantified using the Cumulative Illness Rating
Scale (CIRS) (Linn et al., 1968), which rates 13 domains,
including neurological and psychiatric disorders. The
severity in each domain ranges from 0 (no impairment)
to 4 (extremely severe impairment). The total CIRS
score is calculated by adding together the scores in
the various domains (range 0–52). The Norwegian-
validated version of the neuropsychiatric inventory
(Cummings et al., 1994; Selbæk et al., 2008) was
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applied to assess neuropsychiatric symptoms occurring
in dementia such as visual hallucinations and agitation.
The neuropsychiatric inventory assesses both the frequency
(0–4) and the intensity (0–3) of 12 neuropsychiatric
symptoms. Frequency and intensity are multiplied to
give an item score for each symptom (0–12). A sum
score is calculated by summing the item scores (0–144).
Drug use and classification
Drug names and dosages at baseline were classified
according to the Anatomical Therapeutic Chemical
classification system (WHO Collaborating Centre for
Drug Statistics Methodology, 2014). Psychotropic drugs
were classified into antipsychotics (N05A), anxiolytics
(N05B) hypnotics and sedatives (N05C), antidepressants
(N06A), and anti-dementia drug (N06D). Most anxio-
lytics (N05B) and hypnotics (N05C) are benzodiaze-
pines. The non-benzodiazepine sleeping pills (N05CF)
also act via benzodiazepine receptors and were therefore
classified as benzodiazepines together with N05BA and
N05CD. Polypharmacy was defined as the concomitant
use of five or more drugs, and psychotropic poly-
pharmacy was defined as the concomitant use of three
or more CNS-active drugs. Over-the-counter (OTC)
drugs and dietary supplements without an Anatomical
Therapeutic Chemical-code were not included in the
analysis.
Potentially inappropriate medications and drug–drug
interactions
The NORGEP criteria, which were used to classify any
PIM, are comprised of 36 explicit statements, includ-
ing 21 regarding single drugs and 15 regarding drug–
drug combinations (Rognstad et al., 2009). To identify
possible DDI, a drug interaction database (Norwegian
Medicines Agency, 2014) was used. A 3-point scale is
employed to classify the DDI into the following cate-
gories of increasing severity: (i) “drug interaction only
of academic interest”; (ii) “clinicians need to take
precautions”; and (iii) “drugs should not be combined.”
The prevalence of PIM and DDI is presented at person
level and defined as the percentage of participants who
was prescribed at least one PIM or DDI, respectively.
Statistical analysis
The statistical analyses were performed using the soft-
ware program SPSS, Release 22.0.0.0 (IBM, Inc., Chicago,
IL, USA). The chi-squared test (Pearson) was applied for
categorical variables (sex, dementia diagnosis, degree of
dementia (CDR-GS), and social status). All the other
variables were continuous variables and had a non-
parametric distribution according to the Kolmogorov–
Smirnov test (p<0.05). The Mann–Whitney U-test
was therefore applied. p<0.05 was considered statisti-
cally significant. To assess potential variables associated
with having PIM or DDI, a univariable logistic regression
analysis was performed, followed by a multivariable
analysis. All variables were analyzed for multicollinearity,
and all were found to have acceptable values (variance
inflation factor<2 and tolerance values>0.6). Variables
from the univariable analysis with a p<0.25 were
included in themultivariable analysis. The stepwise back-
ward Likelihood Ratio (LR) method was applied. At each
step, the least significant variable was removed manually
until only variables with p<0.05 remained in the model.
Results
Study sample
The study sample consisted of 251 patients (42%
males), with a median age of 77 years (IQR 71–81).
Please see Table 1 for demographic and clinical base-
line data of the study sample.
Drug use
In the study sample, 96% used one or more medica-
tions. The median number of drugs used per patient
was 4 (IQR 2–6, Table 1). A total of 173 patients
(69%) used at least one psychotropic drug.
Polypharmacy was identified in 113 patients (45%)
and psychotropic polypharmacy in seven patients
(2.8%). Antipsychotics were used by 19 patients
(8%), 12 of them diagnosed with DLB. Both
anxiolytics and hypnotics–sedatives were used by 26
patients (10%), whereas 40 patients (16%) used
benzodiazepines. Anti-dementia drugs were used by
105 patients (42%), while 81 patients (32%) used
antidepressants.
Potentially inappropriate medications
Among the 1110 medications reviewed, 48 PIM were
found according to the NORGEP criteria, which were
accounted for by 35 patients (14%). Five of the
patients (2%) had two or more PIM. Medications rel-
evant to 19 of the 36 NORGEP criteria were identified,
the most common being long-acting benzodiazepines
Drug use in people with mild dementia
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(n=8, 3.2%), combinations with warfarin (n=7,
2.8%), combinations with non-steroidal anti-
inflammatory drugs (n=7, 2.8%), and psychotropic
polypharmacy (n=7, 2.8%). Table 2 gives an overview
of all the PIM. The patients with PIM were more often
women (p=0.037), had higher burden of comorbid
diseases (p=0.027), and used more medications
(p<0.001) compared with those who did not have
PIM (Table 1).
Drug–drug interactions
A total of 191 DDI were identified, accounted for by
103 patients (41%). Two or more DDI were identified
in 36 patients (6%) with eight being the maximum
number of DDI. Four patients (1.6%) used drugs that
“should not be combined” (Table 3). Drug combina-
tions where one should “take precautions” (n=149)
were used by 90 patients (36%). The three most fre-
quent DDI in this group were “increased risk of brady-
cardia” (beta blocking agents in combinations with
cholinesterase inhibitors, n=23, 9.2%), “increased
risk of gastrointestinal bleeding” (acetylsalicylic acid
in combination with selective serotonin reuptake
inhibitors, n=18, 7.2%), and impaired absorption of
oral bisphosphonates (bisphosphonates in combination
with calcium or drugs combined with calcium, n=11,
4.4%). Unfavorable drug combinations of “academic
interest” (n=38) were used by 32 patients (13%). The
patients with DDI were older (p=0.003), had a higher
burden of comorbid diseases (p<0.001), and used
more medications (p<0.001, Table 1).
In both the univariable and in the multivariable
analysis of PIM (Table 4), female sex and number of
medications were significantly associated with having
PIM. In the univariable analysis of DDI, age at
baseline, CIRS scores, and number of medications
(Table 4) were significantly associated with having




To our knowledge, this is one of the first studies inves-
tigating the prevalence and potential variables of
having PIM and DDI in home-dwelling patients with
mild dementia. A total of 45% of the study sample
had polypharmacy, and although 2/3 of them used
psychotropic drugs, only seven patients (2.8%) had
psychotropic polypharmacy. The frequency of PIM
and serious DDI was also low.
Table 2 Potentially inappropriate medications according to the





(n = 251, %)
1 Amitriptyline — —
2 Doxepin — —
3 Clomipramine 1 0.4
4 Trimipramine 1 0.4
5 Chlorpromazinea — —
6 Chlorprothixene — —
7 Levomepromazine 2 0.8
8 Prochlorperazine 2 0.8
9 Diazepam 4 1.6
10 Nitrazepam 3 1.2
11 Flunitrazepam 1 0.4
12 Oxazepam> 30mg/24 t 2 0.8
13 Zopiclone> 7.5mg/24 t 1 0.4
14 Carisoprodola — —
15 Dextropropoxyphene — —
16 Theophylline 1 0.4
17 Sotalol 4 1.6
18 Dexchlorfeniramine — —
19 Promethazine — —
20 Hydroxyzine — —
21 Alimemazine 2 0.8
22 Warfarin + NSAID 2 0.8
23 Warfarin + ofloxacin
or ciprofloxacin
— —
24 Warfarin + erythromycin
or clarithromycin
— —
25 Warfarin + SSRI 5 2.0
26 NSAID/Cox-2 selective
inhibitor + ACE inhibitor/ARB
2 0.8
27 NSAID + diuretics 2 0.8
28 NSAID + glucocorticoid — —
29 NSAID + SSRI 3 1.2
30 Erythromycin
or clarithromycin + statins
— —
31 ACE inhibitor + Potassium or
potassium saving diuretics
3 1.2
32 Fluoxetine or fluvoxamine + TCA — —
33 Beta blocker + cardio selective
calcium antagonist
— —






36 Concomitant prescription of







Total number of potentially
inappropriate medications
48 19
aWithdrawn from the Norwegian market, but can be obtained upon
registration exemption.
PIM, potentially inappropriate medications, NSAID, non-steroidal
anti-inflammatory drugs; ACE inhibitor, angiotensin-converting
enzyme inhibitor; ARB, angiotensin-receptor blocker; SSRI, selec-
tive serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
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Most of the psychotropic drug used was related to
cholinesterase inhibitors, which is an evidence-based
treatment for some types of dementia (O’Brien and
Burns, 2011). The relatively low percentage (42%)
found to be using cholinesterase inhibitors is most
likely related to the study design. Many of the patients
received the dementia diagnosis in the outpatient
clinic on the day of inclusion; thus, the use of these
medications was probably not registered at baseline.
In the present study, the use of antipsychotics, anxio-
lytics, and hypnotics–sedatives was low, while the use
of antidepressants was high compared with other
studies (Hartikainen et al., 2003; Wergeland et al.,
2014).
The relatively prevalent use of antidepressants
(32%) is likely associated with the high frequency of
depression in dementia (Enache et al., 2011). How-
ever, recent evidence suggests limited benefits of anti-
depressants in people with dementia (Banerjee et al.,
2011) and an increased risk of falling (Kuschel et al.,
2014) and other potentially serious side-effects
(Coupland et al., 2011). On the other hand, other
studies found that withdrawal of antidepressants in
nursing homes leads to worsening of depression in
some patients (Bergh et al., 2012) and that treatment
with antidepressants decreased agitation among pa-
tients having Alzheimer’s disease (Porsteinsson et al.,
2014). Thus, more research exploring the benefit and
harm of antidepressants in people with dementia is
warranted.
The patients included in the present study had mild
dementia and a relatively low burden of psychiatric
and other comorbidities, which may explain the rather
infrequent use of the other psychotropic drugs (anti-
psychotics, hypnotics–sedatives, and anxiolytics). Nev-
ertheless, it is interesting that although the patients are
in the early stage of their dementia disease, patients
with DLB are those using antipsychotics most fre-
quently. This might be related to the more severe psy-
chotic and other neuropsychiatric symptoms found in
patients with DLB compared with people with other
dementia diagnoses (Bjoerke-Bertheussen et al.,
2012). This is noteworthy given the high risk for se-
vere adverse reactions related to antipsychotics, which
is a key diagnostic feature of DLB (McKeith et al.,
2005).
Potentially inappropriate medications
In a review, the prevalence of PIM ranged between 3%
and 40% in the older people (Opondo et al., 2012).
This review excluded studies including patients with
dementia, and the few studies reporting the prevalence
of PIM in people with dementia report the prevalence
of PIM to vary between 20% and 46%. Thus, the find-
ing of 14% with PIM is in the lower end. Still, these
studies cannot be readily compared with the present
study because they either use different screening tools,
have a mixed study sample where the patients are in
different stages of their disease, or the study is con-
ducted in a different setting (Lau et al., 2010;
Montastruc et al., 2013; Parsons et al., 2012).
In previous studies, the use of long-acting benzodi-
azepines was one of the most prevalent PIM (Aparasu
and Mort, 2000; Montastruc et al., 2013), which was
also true for the present study where seven of 40
patients taking benzodiazepines used long-acting
benzodiazepines. Side-effects associated with benzodi-
azepines include sedation, falls, and cognitive impair-
ment, and the use should be short-term, but often
remains chronic (Llorente et al., 2000). Further-
more, a recent systematic review concluded that
there is still limited evidence to recommend use of
benzodiazepines in people with Alzheimer’s disease
(Defrancesco et al., 2015). In addition, there is some
indication that the use of benzodiazepines increases
the risk of developing dementia, although it is debated
whether this observation might be due to the
Table 3 Drug–drug interactions identified at baseline in the category “drugs that should not be combined”
Drug 1 Drug 2 Possible clinical consequence
ATC Substance ATC Substance
N03A F01 Carbamazepine N08C A05 Nifedipine Impaired concentration of nifedipine




Increased risk of bleeding due to combined inhibition
of platelet aggregation and coagulation factors
N05A D01 Haloperidol N06A B10 Escitalopram Possible increased risk of severe arrhythmias due to
QT-prolongation
N06D X02 Ginkgo biloba B01A A03 Warfarin Possible increased risk of bleeding
R. Oesterhus et al.
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benzodiazepines being used to treat prodromal symp-
toms of dementia (Zhong et al., 2014).
In studies using the NORGEP criteria, the preva-
lence of PIM ranged between 18% and 35% in the
older people (Bakken et al., 2012; Brekke et al., 2008;
Nyborg et al., 2012). These studies were performed
both in primary and secondary care, which might ex-
plain the differences in prevalence. When comparing
the present results with the studies from primary care
(Brekke et al., 2008; Nyborg et al., 2012), our patients
have few PIM despite the dementia diagnosis. An
explanation for this might be the inclusion of younger
people in the present study (range 50–92 vs. ≥70 years),
and therefore, a healthier study sample as comorbidity
is known to increase with age.
Drug–drug interactions
Only four patients (1.6%) used drugs that should not
be combined. This is in line with a previous nursing
home study using the same interaction database.
Furthermore, the nursing home study had a greater
percentage within the group “clinician should take
precautions” (47% compared with 36% in our
sample) (Søraas et al., 2014). The difference is most
likely due to higher comorbidity in nursing home
patients, resulting in higher drug use.
Again, DDI studies are difficult to compare because
of differences regarding study sample and setting but
most importantly because different drug interaction
databases have been used. A drug–drug interaction is
either due to a pharmacokinetic interaction or a phar-
macodynamic interaction. Not all drug interaction
databases assess pharmacodynamic interactions, and
different databases also categorize the severity of a
DDI differently, which complicates the comparison
further.
This study is based on a longitudinal study that
began inclusion in 2005. During these years, there
has been a focus on reducing the use of psychotropic
drugs in people with dementia, especially the use of
antipsychotics. Kales et al. (2011) found that the use
of antipsychotics in people with dementia was reduced
after the US Food and Drug Administration warned
about increased mortality associated with the use of
antipsychotics. Figures from the Norwegian Prescrip-
tion Database from 2004 until 2013 shows a 32%
relative reduction (a 1.6% absolute reduction from
5.1% to 3.5%) in the use of antipsychotics among
people aged 65 years and older (Norwegian Institute
of Public Health, 2014), which might indicate a change
in the prescription pattern.
Strengths and limitations
The strengths of this study include the inclusion of
people with mild dementia, the use of a standardized
assessment to record clinical and drug use informa-
tion, and pathological confirmation of the diagnosis
in a substantial number of subjects. An additional
strength is the use of the NORGEP criteria. When
using screening tools to analyze PIM, one should pref-
erably use screening tools developed in the respective
area to avoid problems with medication availability,
which has been shown to give a large variation in de-
tected PIM (Chang et al., 2011). The NORGEP criteria
were therefore considered the most applicable for this
study sample because they have been developed in
Norway. Even though the NORGEP criteria were de-
veloped for patients 70 years or older (Rognstad
et al., 2009), we considered them to be applicable to
people with dementia, although some in the study
sample were younger than 70 years of age. Impor-
tantly, the cognitive and functional decline in patients
with dementia increases the sensitivity toward certain
drugs also used by older people (Lindblad et al.,
2006). Several methods have been used to report the
comorbidity in previous studies. Some studies use
number of drugs as a proxy for comorbidity
(Montastruc et al., 2013), while other calculates the
number of diseases (Andersen et al., 2011) or reports
self-rated health (Lechevallier-Michel et al., 2005). A
strength of the present study is the use of CIRS, which
is characterized as a reliable and valid tool to assess co-
morbidity (de Groot et al., 2003) and is found to cor-
relate well with autopsy results (Conwell et al., 1993).
The NORGEP criteria do not assess comorbidity,
which is a limitation. This might reduce the sensitivity
of the screening tool and lead to reduced number of
detected PIM compared with other screening tools like
screening tool of older persons’ potentially inappro-
priate prescriptions (O’Mahony et al., 2015) and Beers
criteria (The American Geriatrics Society, 2012). An-
other limitation is that the patients’ drug history does
not include information about the duration of the
drug treatment and potential changes in drug treat-
ment after baseline, a limitation which is common
for this kind of studies. Nor is there any information
on OTC drugs and whether the patients are compliant.
Many OTC drugs and herbal medicine may lead to
PIM and can also lead to serious DDI. In relation to
PIM, only non-steroidal anti-inflammatory drugs
from the NORGEP criteria are available as an OTC
drug; therefore, the impact is most likely minimal. Ad-
ditionally, this study includes patients recruited from
hospital-based outpatient clinics, which may have led
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to a selection bias and therefore might not be rep-
resentative for the general population with mild
dementia. This potential bias could lead to an under-
estimation of the true prevalence of PIM and DDI,
but there is also a possibility for overestimating the
true prevalence of PIM and DDI if patients with more
severe and complex diseases and comorbidity are
overrepresented. Another limitation is the change in
inclusion after 2007 where only patients with DLB or
Parkinson’s disease with dementia were included. Al-
though the same recruitment sites and other selection
criteria were similar, there is a possibility of creating
two sample groups. Furthermore, very few people
were found to have PIM, and there is a possibility that
this may have resulted in our study not being ade-
quately powered to pick up other predicting factors.
Conclusion
In the present study, few patients with mild dementia
were found to have PIM and severe DDI, indicating
that the quality of prescribing was acceptable. How-
ever, psychotropic drug use was common even in
home-dwelling people with mild dementia despite
limited evidence of benefit. More knowledge is needed
about the potential risks associated with psychotropic
drug use and PIM and DDI in people with mild de-
mentia. Such knowledge has the potential to improve
care, which could benefit quality of life and function





• People recently diagnosed with dementia were
frequently prescribed with psychotropic drugs.
• Potentially inappropriate medications defined by
the NORGEP criteria were seldom prescribed to
patients with mild dementia.
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